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ABSTRACT

Introduction: Breast cancer patients with a depression diagnosis before or after cancer
diagnosis have increased cost, shorter survival time and reduced adherence to hormone
therapy. Treating depression in these patients should improve these outcomes; however,
there is scarce literature on this topic. Currently, no study has determined the association
of concurrent depression while adjusting for a history of depression or treating depression
with antidepressants with cost, survival and adherence to hormone therapy. This study
has two objectives: 1) to determine the association of concurrent depression with cost,
survival and adherence to hormone therapy adjusting for a history of depression 2) to
determine the association of antidepressant use with cost, survival and adherence to
hormone therapy in patients with depression.
Methods: The SEER-Medicare dataset for 2005-2010 was used to address the study
objectives. Breast cancer patients with hormone receptor positive cancers diagnosed
from 2006 to 2009 were identified from the SEER cancer registry. Those who initiated
hormone therapy within a year of cancer diagnosis were included in the initial population.
A depression diagnosis was determined using ICD-9 codes. Those who had an ICD-9
code for depression within a year of cancer diagnosis were included in the final sample.
Antidepressant use was determined from prescription drug claims and those who had at
least one claim after a depression diagnosis were included in the final analysis.
Generalized linear models (GLMs) were used to determine the association of
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antidepressant use with adherence to hormone therapy and the incremental cost of
antidepressant use among breast cancer patients with depression. Kaplan-Meier curves
were used to determine the initial association of antidepressant use with survival.
Results: The final study population was 10,471 hormone receptor positive breast cancer
patients who took hormone therapy within a year of breast cancer diagnosis. Of these
patients, 10% had a diagnosis of depression within a year of breast cancer diagnosis. In
breast cancer patients with depression, 62% took an antidepressant after their depression
diagnosis. Depression was associated with a statistically significant decrease in
adherence (OR 0.81; 0.71-0.93) in the adjusted model. Depression had a statistically
significant 30% decrease in survival in the adjusted model. Depression was associated
with increased cost ($21,978.75) in the adjusted model; however, this was not statistically
significant. Adjusted general antidepressant use in breast cancer patients with depression
had a non -significant reduction in the odds of adhering to hormone therapy (OR .79; .551.14). Those who took antidepressants for a year had a statistically significant increase in
the likelihood of adhering to hormone therapy (OR 2.4; 1.61-3.65). Adjusted general
antidepressant use was not associated with survival in breast cancer patients with
depression. Continual antidepressant use for a year was associated with a statistically
significant 60% increase in survival time in breast cancer patients with depression.
Adjusted general antidepressant use was associated with a $27,840.50 increase in per
patient per year cost; however, this difference is not statistically significant. Continual
antidepressant use for 90+ days was associated with a statistically non-significant
decrease in per patient per year total medical cost.
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Conclusion: Concurrent depression is associated with worse outcomes in breast cancer
patients adjusting for having a history of depression. Continual antidepressant use in
breast cancer patients with depression is associated with improved adherence to hormone
therapy and increased survival time. The benefit of antidepressant use is time dependent
and those who with longer use of antidepressants show more improvement compared to
those who do not. Antidepressant use increases per patient per year total medical cost;
however, this is not a significant increase and continual use might be associated with
decreased cost. Extended antidepressant use in the depressed cancer population provides
positive benefits to these patients by improving adherence to hormone therapy and
survival and potentially reducing cost.
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CHAPTER 1: INTRODUCTION
1.1 Overview

The aim of this chapter is to provide an overview of depression and antidepressant use in
breast cancer patients. A description of breast cancer and its importance will introduce the study
population for the dissertation. The key outcomes for this study are adherence to hormone
therapy, survival and cost for breast cancer patients. Discussion of each outcome begins with the
association of depression followed by the association of antidepressant use for those who are
depressed. This chapter concludes with a statement about the gaps in the literature.

1.2 Breast Cancer in the United States of America
1.2.1 Introduction
Breast cancer is a disease that affects both men and women in the United States and all
parts of the globe. It is also the most costly cancer in the United States1. Simply, breast cancer is
uncontrolled growth of cells in breast tissue that form a tumor2. This disease is rare in men, but
common in women. Female breast cancer is one of the most common cancers in the United
States. If diagnosed at an early stage of tumor growth, female breast cancer has a good
prognosis. Varieties of treatments are available to improve survival in these patients. There are
still gaps in knowledge about the treatment of breast cancer patients despite the plethora of
research on this topic2.
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1.2.2 Epidemiology
It is estimated that 12.3% of women will be diagnosed with breast cancer during their life
with an estimated 231,840 women diagnosed in 2015 in the United States3. The Surveillance
Epidemiology and End Results (SEER) program reports that female breast cancer has an 89.4%
five-year survival rate (2005-2011)3. This survival rate leads to a higher prevalence of women
with breast cancer in the United States, with an estimated 2,975,314 breast cancer cases in 20123.
Prevalence has likely increased over time as the death rate reduced from 26 per 100,000 women
in 2001 to 21.3 per 100,000 women in 20123. Breast cancer affects women differently based off
various demographic characteristics. Women over 50, and Whites in the United States are most
likely to develop breast cancer, while those who are Black have the highest mortality rate in
breast cancer2.
Breast cancer is the general term for cancer of the breast tissue2. This general term
indicates several types of cancers of the breast, which have distinctive characteristics. These
characteristics are the basis for distinct sub types, which have different treatments and survival
probabilities. These subtypes are the presence of the estrogen receptor (ER+), progesterone
receptor (PR+) , human epidermal growth factor receptor 2 (HER2+), or the absence of all 3
receptors (triple negative), or a mix of these combined2. The most common of these subtypes are
ER+ and PR+ tumors2, 4, 5. The significance of ER+ and PR+ tumors is their need for estrogen
and/or progesterone to grow6. These cancers express receptors for estrogen and/or progesterone
that allow them to use these hormones to promote growth. Breast cancers with a majority of cells
expressing one or both of these receptors are considered hormone receptor positive breast cancer
or ER+/PR+6. Those who are hormone receptor positive have a better 5-year survival outlook
compared to those who do not7.
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1.2.3 Treatment
Surgery, chemotherapy and radiation are general treatments for all sub types of breast
cancer2. Surgery is defined as breast conserving surgery where minimal tissue is removed or a
mastectomy where the entire breast is removed2. The type of surgery depends on the
characteristics of the patient and cancer. Radiation is the use of high energy particles to kill
cancer cells and generally follows breast conserving surgery and might follow a mastectomy
depending on the characteristics of the cancer2. Chemotherapy is the use of cytotoxic drugs to
kill cancer cells and can be given before (neo-adjuvant) or after (adjuvant) surgery8.
Chemotherapy is generally the most effective with a combination of drugs; however there is no
combination that is more effective than others2.
Targeted therapy is generally given if the breast cancer sub type is sensitive to targeted
therapy. The most common targeted therapy is hormone therapy to treat ER+ and PR+ breast
cancers2. Women who take hormone therapy for ER+ and PR+ cancers have an increased
survival benefit9, 10. Hormone therapy is given for at least 5 years as this time frame has been
shown to provide the most survival benefit in these patients10. Adherence to hormone therapy is
an issue even with the benefit of increased survival11. Approximately 62% of breast cancer
patients who take hormone therapy adhere to the 5 year regimen12. Improvement is needed for
patients to complete 5 years of hormone therapy.
1.2.4 Types of Hormone Therapy
Hormone therapy contains two major categories, selective estrogen receptor moderators
(SERMs) and aromatase inhibitors (AIs) 2, 13, 14. Each category has the benefit of interfering with
the growth of breast cancer, but they also have unique side effects.
Tamoxifen is the most common drug in the SERM category14. SERMs are estrogen
receptor antagonist because they block the estrogen receptor in breast cells. By blocking the
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estrogen receptor, SERMs prevent tumors from using estrogen to promote growth6, 15. Tamoxifen
is the SERM of choice for treating ER+/PR+ breast cancer13, 15. Tamoxifen has serious side
effects which include blood clots, stroke, hot flashes, fatigue, mood swings and night sweats,
which contribute to non-adherence to tamoxifen therapy14, 16.
Anastrozole, letrozole, and exemestane are common drugs in the AI category. AIs reduce
estrogen in the body by blocking aromatase, a cytochrome P450 enzyme that creates estrogens
from adrenal androgens and testosterone15, 17. Anastrozole and letrozole are non-steroidal AIs
that form a temporary bond with aromatase that keeps aromatase from making estrogens15.
Exemestane is a steroidal AI that binds to aromatase and permanently inhibits aromatase from
creating estrogens15. Due to the clinical effectiveness of these AIs, they are now an alternative
treatment to tamoxifen for postmenopausal and advanced cancers13, 17. AIs also have serious side
effects, which include heart problems, osteoporosis, joint pain and hot flashes, which also
contribute to non-adherence of AI therapy14, 16.
1.2.5 Adherence to Treatment
SERMs alone, AIs alone, or SERMs followed with AIs as therapy for at least 5 years
show the best improvement in survival and reduction of recurrence6, 13, 18. Adherence to hormone
therapy is a concern due to drug side effects and the length of time to gain the benefit of
survival19-22. Menopausal symptoms and sides effects such as cognitive symptoms and
musculoskeletal pain associated with hormonal therapy have been shown to be factors in reducing
adherence to hormone therapy19, 20. Studies observing adherence show a decrease in adherence
over time for both SERMs and AIs12, 22-24. Reduced adherence over time is a concern as women
have poorer survival with reduced adherence12, 22, 23, or conversely, those who are adherent show
improved survival9, 25-28.
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Several studies have identified factors that predict non-adherence22, 23, 29-32. Side effects
were the most common reason for non-adherence found in these studies29, 30, 32. Other reasons
affecting adherence to hormone therapy include number of comorbidities, tumor size, using both
a SERM and AI, and age. One study did find that a decrease in the quality of life was a predictor
of non-adherence29. Adherence to hormone therapy is associated with several factors, which
include patient characteristics, switching to an AI from a SERM and quality of life.
Non-persistence or discontinuing therapy is a particular type of non-adherence that is also
important in hormone therapy13, 33. A person can be considered persistent but not adherent if they
consistently take hormone therapy for 5 years but do not adhere to the recommended regimen
during this time. For example, a person may have been 10 days late to refill their hormone
therapy but they do not stop taking it completely. This person would be persistent but not
adherent. Studies have found that non-persistence is an issue for breast cancer patients taking
hormone therapy12, 13, 33, 34. These studies report that age, comorbidities and poverty level were
associated with non-persistence. A study by Hadji indicated a switch of therapy and depression
were also associated with non-persistence33.
1.2.6 Cost
Breast cancer costs are categorized as direct or indirect cost. Direct costs include all
medical expenses incurred by breast cancer patients. These costs can be breast cancer specific,
all cost incurred by the patient or broken down to medical, pharmacy and other cost. Indirect cost
includes loss of productivity, time family spends caring for the patient, and life style changes due
to breast cancer.
Direct breast cancer cost was estimated to be $18.1 billion in 2014 in the United States1.
Continuing care, including hormone therapy, cost $7.6 billion (42%) of the total cost for breast
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cancer in 2014. Within the first year of diagnosis, 39% of Medicare payments were direct cost of
treatment in breast cancer patients in 2002.
Breast cancer also has a high indirect cost. Employers in the United States lost $12.1
billion in 2005 due to breast cancer deaths for those over 201. This estimate excludes other
indirect cost such as lifestyle changes. Lifestyle changes would include increased exercise, such
as yoga classes, and cosmetic changes (wigs). The patient incurs these extra costs, but they are
not accounted for in medical cost or loss of work for an employer.
Direct and indirect costs of female breast cancer make it the most costly cancer in the
United States35 As indirect costs are hard to measure, studies have focused on direct cost,
particularly the cost associated with hormone therapy. Non-adherence to hormone therapy is a
major contributor to the high cost of breast cancer36. Those who were not adherent to hormone
therapy had significantly higher medical cost during the 4 years of hormone therapy observed.
There was no statistical difference in total cost (medical plus pharmacy) between those who were
adherent and those who not adherent36.
. 1.2.7 Summary
Breast cancer affects many women in the United States and has several sub types that
allow for specific treatments depending on the category. The most common sub type is hormone
receptor positive, which is treated with hormone therapy. Adherence to hormone therapy is an
issue due to the length of time of the therapy and side effects. Breast cancer is also the most
costly cancer in the United States with non-adherence to hormone therapy contributing to the high
cost of breast cancer.
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1.3 Depression and Breast Cancer

Around 25% of breast cancer patients will be diagnosed with depression37-42. The
prevalence of depression in breast cancer ranges from 5% to 50% depending on the population
studied and how depression was classified37-43. Diagnosing depression is difficult as those taking
chemotherapy have side effects that overlap with symptoms of depression42. There is also
evidence that those taking hormone therapy will exhibit depressive symptoms as well44.
Chemotherapy and rapid decline of estrogen due to hormone therapy is linked to cognitive
impairment and depression40, 41, 45. There is also evidence that breast cancer patients are prone to
depression due to a change in cytokine levels from the cancer and chemotherapy45-49.
The prevalence of depression in breast cancer is a concern due to its effect on adherence
and survival. Studies have established that depression has a negative effect on adherence in
chronic diseases such as diabetes and hypertension50. The association of depression with
adherence to hormone therapy in breast cancer is not consistently reported in the literature. A
diagnosis of depression was associated with no effect or decreased odds of non-adherence to
hormone therapy according to a review by Van Liew16. Van Liew’s review indicated that having
at least on comorbid condition was a predictor of better adherence. Other views on the
association of depression with adherence to hormone therapy are seen in other studies outside of
Van Liew’s review20, 33, 51, 52. These studies indicate a negative association of depression with
adherence to hormone therapy. Further, a meta-analysis of the literature showed depression is
negatively associated with adherence to hormone therapy53. Van Liew’s study is likely indicating
that those who have a comorbid condition (i.e. depression), are more likely to be monitored by a
physician and will be more adherent to hormone therapy as they are seeing a physician more
often compared to if they did not have the comorbid condition.
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Depression also has a negative impact on survival in breast cancer patients. Goodwin
found a 42% increase in the risk of 3 year mortality for those who were depressed in the SEERMedicare population54. Studies that used different datasets report similar results55-57. There is a
biological mechanism for reduced survival in depressed cancer patients. Studies show that breast
cancer patients have increased levels of cortisol, a hormone that controls glucose intake by cells,
which could lead to tumor cells exhibiting resistance to cortisol stimulation. This resistance
allows tumor cells to dominate glucose absorption and grow58. Those who are depressed also
exhibit increased levels of neuroendocrine hormones related to stress that promote tumor growth
as well58, 59. Breast cancer patients who exhibit depression after surgery have an impaired
immune system response to breast cancer cells, indicating they are not able to fight off the cancer
and potentially lead to a shorter survival time59.
Cancer patients with depression have higher cost compared to those without depression.
Breast cancer survivors who have depression show almost double the cost compared to those who
do not have depression60.
1.3.1 Summary
Depression in breast cancer is a concern it negatively affects adherence to hormone
therapy, survival and cost. Those with depression have poor survival for two reasons. The first is
depression is associated with poor adherence to hormone therapy. Adhering to hormone therapy
improves survival and it has been shown that breast cancer patients who do not adhere to
hormone therapy have worse survival compared to those who do adhere to hormone therapy.
Depression also potentially weakens the body’s ability to fight breast cancer and lead to poor
survival since the cancer will take over the body if allowed. Those with depression also incur
higher cost from increased healthcare utilization (direct medical and pharmacy) either by
increased hospitalizations or increased physician visits and additional prescriptions.
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1.4 Treatment of depression in breast cancer
1.4.1 Overview
Antidepressants and group therapy are two treatment modalities for depression in breast
cancer patients61, 62. Several studies show that group therapy is effective in treating depression
symptoms in the breast cancer population62-66. Antidepressants are also effective in treating
depression in breast cancer patients67-70.
Antidepressants have potential additional benefits in breast cancer beyond treating
depression. They have been shown to help alleviate menopausal symptoms, hot flashes, etc., in
breast cancer patients on hormone therapy71. This is probably due to their estrogenic effects72.
Antidepressants also show anti-tumor effects in vitro73.
Some antidepressants interact negatively with hormone therapy. The most commonly
prescribed antidepressant, selective serotonin reuptake inhibitor (SSRI), negatively interact with
tamoxifen. Tamoxifen is metabolized by cytochrome p450 2D6 (CYP2D6) into its active
metabolites, which have a 100 fold increase in the ability to block the estrogen receptor74. SSRIs
inhibit CYP2D6, which reduces the active metabolites of tamoxifen in breast cancer patients on
tamoxifen therapy74. Studies have addressed the potential negative interaction of SSRIs with
tamoxifen. Three studies found no effect of SSRIs on tamoxifen’s protective effect against
recurrence75-77. One study reported the SSRI paroxetine did block tamoxifen’s protective effect
on survival78. Following these studies, an editorial by Breibart indicated that certain SSRIs, like
paroxetine, should not be given concurrently with tamoxifen as they are considered strong
inhibitors of CYP2D6. SSRIs considered milder inhibitors of CYP2D6 could be given
concurrently with tamoxifen79. This concern is reflected in a transition from use of SSRIs
regarded as strong inhibitors to those that are weak inhibitors of CYP2D6 in tamoxifen users over
time80.
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1.4.2 Depression treatment and cancer outcomes
As stated previously, depression is associated with worse outcomes; therefore, treating
depression should be associated with improved outcomes. In the scare literature determining an
association of depression treatment with outcomes, treating depression potentially improves
outcomes in those with depression. Breast cancer patients with depression who were treated with
the antidepressant fluoxetine showed improved completion of both chemotherapy and hormone
therapy81. Depressed metastatic breast cancer patients who had reduced depression scores had
improved survival82. Treating depression in breast cancer has mixed results on cost. One study
finds no difference between the treated (group therapy) and untreated groups for both cost and
utilization83. A literature review indicated that psychosocial interventions are inexpensive and do
not significantly increase cost in the treated group and found that this intervention was cost
effective as it increased quality adjusted life years84. A Canadian study in cancer patients
reported a 23% reduction in total cost in breast cancer patients with depression who received
group therapy85. In diabetes, a chronic condition like cancer, treating depression systematically
showed increased total cost in the first year but reduced total cost by the second year86. Another
study found short term cost for treating depression with group therapy is significantly higher
while those on antidepressants are not significantly higher87. At this time, it is unknown how
treating depression with antidepressants over the course of hormone therapy will influence cost.
Treating depression with group therapy or antidepressants potentially improves
adherence to hormone therapy and survival in breast cancer. Breast cancer patients with
depression do have higher cost if they are treated with antidepressants or group therapy; however,
if treatment persists over time, cost could be reduced.
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1.5 Summary

Breast cancer is a costly disease that affects a large proportion of women. Breast cancer
has several sub types that are characterized by distinct clinical markers. The most common sub
type is hormone receptor positive where the cancer cells express the estrogen and/or the
progesterone receptor. These cancers are able to use hormones to promote their growth so the
traditional therapy is to block these receptors either directly using SERMs or at the source using
AIs. Due to side effects and length of hormone therapy, adherence and persistence to hormone
therapy are clinically important issues. There is no consensus on how depression affects
adherence and persistence in breast cancer; however, it is likely that there is a negative
association of depression with adherence to hormone therapy. Cost and survival are both
negatively affected by depression. Treating depression potentially improves adherence and
survival and initially raises cost; however, cost might be reduced over time.
There are gaps in the knowledge of how depression and antidepressant use impact
adherence to hormone therapy, cost and survival in breast cancer patients. The association of
depression with adherence to hormone therapy, survival and cost adjusting for a history of
depression is not known. The association of antidepressant use with adherence to hormone
therapy, survival and cost in the majorly depressed population is not known.
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CHAPTER 2: LITERATURE REVIEW
2.1 Introduction

This chapter will present the current literature that describes the effect of depression and
depression treatment on adherence to hormone therapy, survival and cost in breast cancer
patients. This chapter will begin with a description of adherence, survival and cost followed by a
detailed analysis of the relevant studies. Each analysis will include the purpose of the study,
source of the data, study population, how relevant variables were operationalized, sample size,
analysis used, relevant results, discussion of results and overall conclusion from the study. For
each subsection, non- significant results are presented first followed by significant results. Each
subsection will conclude with a summary of the presented studies followed by the identification
of the gap in the literature. Each major section will conclude with a summary of all presented
literature and the gaps found in the presented literature. This chapter will conclude with the aims
and hypotheses of this study.

2.2 Definitions of Outcome Variables

2.2.1 Adherence
Medication adherence is the extent to which a patient follows their treatment regimen
over a period of time51. Non-persistence or discontinuation is defined by an extended period of
time between prescription drug fills, for the same drug, and indicates a patient stopped taking
their therapy33. The length of time that defines when a person is non-persistent ranges from 90 to
over 180 days between prescriptions in breast cancer patients33, 52. A patient who is not persistent
is also considered non- adherent. Pill count, electronic monitoring, self- report, medication
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possession ratio and percent days covered are ways to measure adherence in breast cancer
patients taking hormone therapy20, 22, 51, 88.
2.2.2 Survival
Survival in cancer has two components, namely length of time from diagnosis to death,
and cause of death, specifically cancer-specific or other cause54, 55, 57, 89.
2.2.3 Cost
Cost can be calculated several ways in the health care setting depending on the
perspective. From a societal perspective, cost would include all direct medical cost in addition to
other indirect cost. Examples of indirect cost are absence and loss of productivity to a company
due to illness and transportation to and from a health care facility. From the patient perspective,
cost would include direct medical out-of-pocket cost in addition to the transportation and loss of
salary due to illness. In the literature, the focus is generally on direct medical cost.

2.3 Association of Depression with Hormone Therapy Adherence, Survival and Cost
in Breast Cancer

2.3.1 Association of depression and adherence to hormone therapy
Table 2.1 summarizes several studies that examined the association between adherence to
hormone therapy and depression. There is lack of consistency in the conclusions about the
association of depression with adherence to hormone therapy. Studies ranged from a significant
improvement in adherence to hormone therapy to a significant reduction in adherence to hormone
therapy for those who are depressed.
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Four studies found improvement (significant and non-significant) in adherence to
hormone therapy for those who were depressed33, 51, 90, 91. All four studies were in European
populations and two used the same dataset. Only two of these studies were designed to determine
an association of depression with adherence33, 90. The study by Huiart is unique in the breast
cancer literature as it focuses on a younger population (<40 years of age)90. This study is not
generalizable to the general breast cancer population because most breast cancer patents are older
(>60), and there are differences in how those who are 40 are affected by breast cancer compared
to those who are over 60. Huiart's study also has a smaller sample of 246, with only 49 being
depressed, which also limits generalizability. It is likely that these results (RR=.8 for nonpersistence) would be significant with a larger sample size. Hadji's study is in the elderly
population, but focuses on the type of care a patient received in Germany33. This study is in the
elderly population and is generalizable to these patients. Of note, the hazard ratio of .92 for
depression is closer to one compared to Huiart's study, but with a sample of 12,412; a significant
result is expected. A distinct difference between these two studies is Huiart identified depression
at 10 months after breast cancer diagnosis compared to Hadji who identified depression before
breast cancer diagnosis. A potential explanation for consistently observing an indication of a
positive association of adherence to hormone therapy with depression is those who are depressed
are more likely to see a physician more often, which would lead to them to be more adherent to
hormone therapy because they are seeing a physician more regularly compared to those who are
not depressed. Of interest, Ziller's study indicated a differential effect of baseline depression on
hormone therapy adherence between those on tamoxifen vs AIs51. The design of this study was to
characterize these patients in a non-experiment setting, not determine predictors of nonadherence. Those on tamoxifen with baseline depression showed improved adherence to therapy
(non-significant OR=1.22) compared to those on AIs with baseline depression who showed
reduced adherence to therapy (non-significant OR=.96). With samples larger than 65 and 72 for
tamoxifen and AI users, respectively, these results would likely become significant. Like Hadji’s
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work, this study was in the elderly population and potentially generalized to the general breast
cancer population.
A negative association of depression with adherence to hormone therapy was indicated in
five other studies20, 29, 52, 88, 92. Of these studies, three showed a non-significant association of
depression to adherence to hormone therapy29, 52, 92. The study by Grunfeld indicated that those
who were not adherent to hormone therapy had a non-significant increase in depressed mood
compared to those who were adherent, based on a sample with only 13 who were not adherent92.
Like Ziller’s work, this study aimed to characterize patients who were non- adherent to hormone
therapy. The other two studies that showed a non-significant decrease in adherence to hormone
therapy for those who were depressed did focus on predictors of adherence to hormone therapy29,
52

. These studies did not directly measure depression and relied on self-report or medication use

to distinguish patients who had depression. Concurrent depression was associated with increased
risk of discontinuing therapy in both studies (non-significant). Kemp showed a significant
increase in the risk of discontinuing therapy for those who were concurrent/newly depressed
(HR=1.19) before adjusting for covariates such as tumor size and clinical stage. When adjusted
for all covariates, this increased risk was not significant. Kemp also examined a history of
depression and found a non –significant increase risk of discontinuing therapy52.
Two studies were designed to determine the association of depression with adherence to
hormone therapy, and they both found a significant negative association of depression with
adherence20, 88. Both of these studies used a depression scale to determine depression status and
used an alternative to pharmacy claims to determine adherence. Data were collected via
electronic monitoring of pill caps and in person interviews in Bender's study. A strength of
Bender's study is the use of random coefficients modeling, which allows the use of repeated
measures for adherence over time. As adherence changes over time, this model allows for this
variation in determining predictors of non-adherence. The parameter for univariate analysis
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predicting adherence for the Beck depression score (a higher score indicates more severe
symptoms) was

-.8845 (p<.01) at baseline and -.3106 (p>.05) as a time dependent variable.

This indicates that a higher Beck score at baseline is associated with reduced adherence (p<.05)
and indicates a negative association over time (p>.05). This study’s sample of 91 limits the
power to detect statistically significant differences and a larger sample might have shown a
statistically significant decrease in adherence for those who developed depression during the
study. A limitation for this study is that the analysis did not account for the other variables in the
study, which would alter the effect of the Beck score on adherence. Of note, adherence was a
continuous variable and the analysis was for a 1% increase in days of therapy taken. This
consideration indicates that the estimates are likely conservative estimates and those with more
depressed symptoms have a significantly reduced likelihood of adhering to hormone therapy.
Klepin's study of cognitive factors associated with adherence to tamoxifen and raloxifen
(Co-STAR) used 6 month follow-up information taken in-person and a baseline standardized
neuropsychological test that consisted of several cognitive tests that covered different areas of
cognition88. These areas include memory, verbal fluency and global function. This is a nested
study from a randomized clinical trial examining differences in tamoxifen and raloxifen.
Adherence was measured every 6 months by pill count when a patient came into the clinic for the
randomized trial and was condensed to a single measure for the entire period in this follow up
study. Multivariate logistic regression showed that a higher baseline depressive symptom score
was associated with a significant 13% increase in the odds of non-adherence. This result
indicates that more depressive symptoms at baseline are significantly associated with nonadherence to hormone therapy. Of note, this study was not in the breast cancer population, but
those who were at risk for breast cancer. One limitation is the use of a condensed adherence
variable instead of repeated measures. A more appropriate analysis would be the use of the 6month measures in a repeated measures analysis instead of a single measure for up to 5 years.
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There appears to be a negative association between depression and adherence. The
studies that indicated a positive impact of depression on adherence do not provide support for this
association in the general breast cancer population. The use of a young population or small
sample size indicates limited external validity for Huiart and Ziller51, 90. The only claims analysis
done that indicated a positive association assessed discontinuation and not adherence33, 91. In the
claims analysis they did not account for a potential increase in utilization of physician visits due
to depression as a potential reason for the positive association observed. As these analyses
included the type of physician practice a person visited, the negative effect of depression might
have been observed in the poorer physician practice and the depression variable itself indicates
the association of more physician visits with increased persistence. These studies do not support
a strong positive association of depression with adherence to hormone therapy. Of the five
studies indicating a negative association of depression and adherence to hormone therapy, three
used prospectively collected data from a clinical trial or other project20, 52, 88. Only two of these
studies directly obtained information on depressive symptoms20, 88 and only one used a large
sample size88. Only Bender, used a repeated measures analysis for adherence over time. As
adherence to hormone therapy drops over time, using repeated measures allows for a more
detailed analysis of predictors of non-adherence22. No study reports the association between
depression and adherence to hormone therapy using a large database with a repeated measures
design.
2.3.2 Depression and survival
Table 2.2 summarizes four studies that examined the association between survival and
depression. All studies found a significant reduction in survival for those with depression. These
studies focus on a prior diagnosis of depression and not concurrent depression. Each study
provides a different perspective on the association between depression and survival in breast
cancer patients.
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Onitilo's study used a general approach that observed four groups of people from the NHANES
population55. These groups were those with no cancer without depression, no cancer with
depression, cancer with no depression; and cancer with depression. Mortality was determined
either with the National Death Index or by a proxy interview that determined a patient’s vital
status. The authors reported hazard ratios of 1.42, 1.24 and 1.7 (p<.05 for all) for those with
cancer without depression, no cancer with depression and cancer with depression, respectively
compared to those with no cancer without depression adjusting for various demographic
characteristics. The authors reported a breast cancer specific hazard ratio of 1.27 (p>.05) that
adjusted for various demographic characteristics. The sample size of 136 for all breast cancer
only patients is likely too small to detect significant differences between those with depression
and those without depression. A limitation of this study is the inability to adjust for cancer
specific confounders, which would influence survival, such as stage of cancer that is an indication
of cancer severity. Another limitation of this study is the inability to determine if depression was
diagnosed before or after breast cancer diagnosis.
Hjerl’s more focused design found mixed results for the direct association of depression
with survival in early and late stage breast cancer patients 89. In the 10,382 women with early
stage breast cancer those with depression before or after cancer diagnosis had relative risks of
1.23 (p>.05) and 1.73 (p<.05), respectively for death due to all causes. Relative risks for the
10,211 late stage breast cancer patients were 1.34 (p<.05) and .96 (p>.05) for those with
depression before or after breast cancer diagnosis respectively. All risks were adjusted for
clinical characteristics that would affect survival and those with late stage cancers were
additionally adjusted for tumor size and the number of positive lymph nodes. This study
indicated that depression increases the risk of death due to all causes in early stage breast cancer
while only preoperative depression significantly increases the risk of death due to all causes in
late stage cancer patients. This is the first study to indicate that the timing of depression may
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have a differential effect on survival depending on the stage of cancer. The strength of this study
is the large sample size and additional adjustments for confounders. Another strength is the
generalizability to a broader breast cancer population; however, this study used data from 19781993 from Denmark. An updated study is needed to determine if these results are applicable to
the current population.
Vodermaier focused on 1,646 early stage breast cancer patients from two cancer centers
who did or did not have a prior diagnosis of depression57. Those with a prior diagnosis of
depression had a 154% (p=.02) increased risk of death due to all- causes adjusting for clinical and
demographic characteristics. A strength of this study is the comprehensive adjustment for
confounders and a large enough sample size to generalize to a broader breast cancer population.
Goodwin’s SEER-Medicare study is the only United States claims based study to
examine the impact of depression on survival in breast cancer54. The purpose of this study was to
determine if a prior diagnosis of depression had an effect on 3-year survival in breast cancer
patients. The final population of 24,696 breast cancer patients was analyzed. A prior diagnosis
of depression had a 142% increase in the risk death within 3 years of diagnosis (p<.05) adjusting
for some con founders. A limitation of this study was that tumor type (ER/PR + etc.), initial
surgery, radiation use, chemotherapy use, tumor size and grade were not included in the analysis.
These are all important factors that affect survival in breast cancer. Of note, this study used data
from 1993-1996 and an updated analysis is need to determine the impact of prior depression on
the current United States breast cancer population. An important strength is the use of SEERMedicare, which is a representative database for all Medicare breast cancer patients in the United
States. A study is needed to determine the effect of prior depression on survival adjusting for all
confounders in the current SEER-Medicare population.
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The literature shows a prior diagnosis of depression is associated with a significantly
increased risk of death in breast cancer patients. Only one study accounted for the effect of
concurrent depression on survival, and was in a Denmark population from 1978-1993. The only
United States claims study looked at a prior diagnosis of depression and did not fully adjust for
all confounders. There is no claims based analysis in the United States to determine the impact of
concurrent depression on survival that also adjusts for a history of depression and all confounders
in breast cancer.
2.3.3 Depression and cost
Table 2.3 summarizes the studies that examine the association between cost and
depression. Only two studies determined the incremental cost of depression in cancer, and
neither specifically looked at breast cancer. Other studies did not determine the incremental cost
of depression, only the cost in patients with depression compared to those without depression.
Only one study specifically examined cost in women with breast cancer and depression.
The study that specifically assessed cost in depressed breast cancer patients reported that
those with depression incurred $15,471 annually compared to $8,297 in breast cancer patients
without depression60, 93. Jeffery used the Military Data Repository (MDR) for this study and
calculated costs as the total cost the Department of Defense paid to providers during fiscal year
2009. The final sample included 11,014 cancer patients, 2,851 (26%) breast cancer, for analysis.
Incremental cost of depression in cancer patients was not calculated, and each cancer was
analyzed separately, but the results were not reported in the primary article. A news article on
this paper reported breast cancer specific results60. A limitation of this study is the use of a
military database, which is not generalizable to the general breast cancer population. This is the
only study to show that depressed breast cancer patients incur higher cost compared to nondepressed breast cancer patients.
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Only one study determined the incremental cost of depression in cancer, which includes
breast cancer. Pan determined the incremental cost of depression in all cancer patients in the
Medical Expenditure Panel Survey (MEPS) population94. Cost was calculated as total health
expenditures, which include all insurance payments, and out of pocket payments by the patient
and reported in 2009 dollars. Ordinary least squares (OLS) of log transformed cost and
generalized linear models (GLM) with a log link and Gaussian distribution were used to
determine the incremental effect of depression on cost. OLS showed a 32% increase in total
cost, 16% increase in outpatient and 107% increase in prescription cost for those who were
depressed adjusting for demographic and clinical confounders (p<.001 for all). GLM showed that
those with depression incurred an extra $2,213 total cost (p<.05) and $913 (p<.01) prescription
cost compared to those without depression adjusting for clinical and demographic confounders.
GLM also showed that those who are depressed had a reduction of $329 for outpatient cost. One
limitation of this study is the inability to account for cancer specific factors such as stage that will
influence cost as those with more severe cancers will have higher cost compared to those with
less severe cancers. A strength of this study is the generalizability to all United States cancer
populations as MEPS is nationally representative. Another strength is the use of a GLM with a
log link and a Gaussian distribution to account for the skewed nature of cost.
Jayadevappa used SEER-Medicare to the effect of depression on cost in men with
prostate cancer95. Cost was calculated as direct medical cost Medicare paid in reimbursements
and reported in 2009 dollars using a 5% discount rate. A generalized linear model with a log-link
and gamma distribution reported the effect of depression on cost. Depression diagnosed during
treatment showed significantly increased cost (1.52 odds to 1.34 odds) for the years 1 to 4 after
cancer diagnosis and 1.43 odds the last year before death. Depression diagnosed after treatment
showed significantly increased cost (1.51 odds to 1.89 odds) for years 2-5 and 1.26 odds the last
year before death. A limitation of this study is the authors only report the odds and not the actual
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cost even after they explain that is the advantage of using GLM. The authors did not take
advantage of this tool to report the incremental cost of depression in prostate cancer. Another
limitation is that they did not adjust for cancer specific variables such as stage, tumor size, or
surgery type.
The literature shows that depression increases direct medical cost in cancer. Only one
study showed the incremental cost of depression in cancer, and it was unable to account for
cancer specific confounders. Two studies use a GLM to examine cost, which is an appropriate
analysis to account for the skewed nature of cost. There is one study to compare the cost incurred
by depressed breast cancer patients to non-depressed breast cancer patients; however, the study
did not determine the incremental cost of depression and was in a select breast cancer population
that did not reflect the general breast cancer population. No study in the literature determined the
incremental cost of depression in breast cancer using generalized linear models.
2.3.4 Summary of Depression in Breast Cancer
The literature for depression and breast cancer shows that depression has negative effects
on adherence to hormone therapy, survival and cost. The literature that examined the association
between depression and adherence contains differing results. The studies that indicated a positive
association between depression and adherence have two limitations: 1) a unique population not
indicative of the general breast cancer population and 2) potentially increased monitoring due to
more doctors’ visits because of a depression diagnosis. Studies that showed a negative
association of depression with adherence were in a prospective setting and generally used a single
adherence measure. There has not been a retrospective claims study using repeated adherence
measures to examine the effect of depression on adherence to hormone therapy. Studies
examining the association of depression with survival all found a significant decrease in survival
for those who were depressed. These studies focused on a prior diagnosis of depression and not
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depression during breast cancer. The one generalizable United States study did not account for
several confounders in their analysis. No study has examined the impact of depression during
breast cancer on survival that accounts for all available confounders in the United States. Cancer
patients with depression have increased cost and the only study that specifically observed breast
cancer patients did not determine the incremental cost of depression and was in a unique
population. Other studies that determined incremental cost of depression in cancer patients used
a GLM, a model that is able to account for the skewed nature of cost without transforming cost
before the analysis. The incremental cost of depression in breast cancer patients has not been
determined using a GLM.

2.4 Breast Cancer and Treatment of Depression

2.4.1 Adherence and depression treatment
Table 2.4 summarizes three studies that examine the association between adherence to
hormone therapy and antidepressant use. These studies show mixed results on this association
that range from significant improvement to a significant reduction in adherence to hormone
therapy; however, none of these studies focused on those who had a diagnosis of depression.
Two studies indicated a reduction in adherence to hormone therapy for those taking
antidepressants19, 24. Trabulsi reported that antidepressants negatively affect adherence to
hormone therapy in 4,715 elderly breast cancer patients24. Antidepressants at baseline reduced
adherence by 4.7% (p=.004) adjusting for various clinical and demographic characteristics. A
limitation is that depression was not controlled for in the analysis, which potentially indicates that
antidepressants are a proxy for depression. Therefore, these results do not show the association
of antidepressant use with adherence to hormone therapy in the depressed population. Another
limitation of this study is the use of a single measure of adherence for 5 years instead of repeated
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measures. Using a repeated measures analysis would allow patients to be followed over time.
The study by Cluze did observe depressive symptoms and still found a reduction in adherence for
those on antidepressants19. In the univariate analysis, antidepressants had a 1.91(p>0.2) increase
in the odds of early non-persistence while those with a CES-D score >23 (French cutoff for
depression96) had a 0.76 (p>0.2) decrease in the odds of early non-persistence. Antidepressants
also had a 1.36 (p>.2) increase in the odds of late non-persistence and depression had a
2.48(p>.2) increase in the odds of late non-persistence. The p-value in the univariate analysis did
not meet the required <.2 cutoff to be included in the multivariate analysis for antidepressant use
and depression. As these odds ratios are not adjusted, antidepressant use is likely a proxy for
those with major depression as indicated above. As depression was not accounted for in the
analysis in both papers, antidepressants might decrease the risk of non-persistence in breast
cancer patients with depression.
Navari’s study is the only one that examined the effect of antidepressants on completion
(adherence) to hormone therapy in 193 breast cancer patients with depressive symptoms81. The
fluoxetine (antidepressant) group had a significantly higher rate of completing adjuvant therapy
(87%) compared to placebo (50%) (p<.01). A limitation of this study is the short observation
period, particularly for hormone therapy. As patients take hormone therapy for at least 5 years,
the concern of non-adherence is after the first year or two. This study was also not in clinically
depressed patients, but it is likely that those who are clinically depressed would benefit more
from treatment than those who are not. Another limitation is it is not generalizable past early
stage breast cancer patients with mild depressive symptoms. The strength of this study is its
internal validity that comes with a double blind randomized controlled trial. This study indicates
potential causality between fluoxetine treatment and completing adjuvant treatment at 6 months.
The literature is conflicted on the impact of antidepressants on adherence to hormone
therapy; however, only one study observed those with any depressive symptoms. The two studies
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that indicate a negative effect of antidepressants on adherence to hormone therapy do not account
for a diagnosis of depression. In these studies, antidepressant use is likely a proxy for depression,
which has been shown to negatively effects adherence to hormone therapy. The one study that
established that antidepressants improve adherence was in a small sample and in the nonclinically depressed population. As an association was established in Navari’s study, a large
study in the clinically depressed population will determine if these results are generalizable to the
larger breast cancer population. No claims-based study to determine the impact of antidepressant
use on adherence to hormone therapy has been done in the clinically depressed breast cancer
population.
2.4.2 Survival and depression treatment
Table 2.5 summarizes five studies that examine the association between survival and
depression treatment. Three studies examined antidepressant use for depression treatment and
two studies examined group therapy for depression treatment.
The two studies that examined group therapy were both randomized controlled trials and
were not in a clinically depressed population64, 82. The study by Goodwin did not show any
improvement in survival for those in group therapy (median 17.9 months survived) compared to
control (median 17.6 months survived)64.

Giese-Davis showed a significant increase in survival

time for those who had lower depressive scores (median 53.6 months) compared to those did not
(25.1 months)82. Of note, Giese-Davis did not determine if group therapy was effective in
reducing depressive symptoms compared to the control group. These studies indicate that in the
non-depressed population, survival is improved by decreasing depressive symptoms not with
group therapy.
Of the three studies that examined the association of antidepressant use on survival, only
one was in a group that exhibited depressive symptoms and none were in a clinically depressed
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population28, 70, 78. In the two studies with no depressive symptoms, a mixture of results were
reported. Weaver reported that those who use CYP2D6 inhibitors (half of which were
antidepressants) reduced the risk of death by 17% (p>.05) adjusting for adherence and clinical
and demographic characteristics28. There are two considerations when examining these results.
The first is this was not in the depressed population and the reduction could be significant in the
depressed population. The second is the effect could be due to the inhibitors that were not
antidepressants examined in this study instead of the antidepressants. Also, there could be
differential effects of specific antidepressants, which are not captured in this study. The study by
Kelly indicates that there are differential effects of antidepressants on survival for breast cancer
patients on tamoxifen78. The adjusted cox proportional hazards model indicated a potential
positive association for the antidepressant fluoxetine and survival, reduced risk of death due to all
causes by 5% (p>.05). The adjusted model indicated a negative association of other
antidepressants with survival; most associations were not statistically significant. Paroxetine had
a statistically significant 146% increase in the risk of death due to all causes. There are two
important factors to consider in interpreting these results. The first is this may not be in the
depressed population. Antidepressant use could be a proxy for depression, which is one reason
why there is a potential negative association indicated in this study. If antidepressants are a proxy
for depression, then there is no other variable in this study that would indicate depression is being
treated by an antidepressant. This study would then be reporting the association of depression
and not antidepressant use. Also, antidepressants could also be prescribed for other reasons that
are not related to depression, such as treating menopausal symptoms71. In the depressed
population, it is possible that antidepressant use improves survival. The second is this was in a
tamoxifen only population and the only antidepressants examined were SSRIs. In tamoxifen
users, there is a debate in the literature about the potential negative effects of SSRIs on tamoxifen
metabolism and benefits74, 76, 97, 98. Published literature indicates that SSRIs fluoxetine and
paroxetine potentially reduce the effectiveness of tamoxifen, but other SSRIs and other classes of
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antidepressants do not reduce tamoxifen’s effectiveness98. Of note, there has been no debate
about SSRIs for those who use aromatase inhibitors.
Only one study examined the impact of antidepressant use on survival in cancer patients
exhibiting depressive symptoms. Fisch reported a non-significant decrease in median survival
time for those who took fluoxetine (6 months) compared to placebo (9 months) in a clinical trial
by the Hoosier Oncology Group70. The strength of this study is the internal validity to determine
causality for the effect of fluoxetine on survival. The randomized clinical trial design balances
both observed and non-observed confounders between groups and the only difference between
these groups is the taken drug. If there is only one difference between these groups, that
difference is the cause for the reported results. One limitation is these patients were not clinically
depressed, so there could be a positive effect of fluoxetine on survival. Of interest, the survival
curves do cross in the second year of follow up with those on fluoxetine exhibiting a longer
survival time compared to those on placebo. This indicates that a positive effect of antidepressant
use is seen over time rather than immediately in depressed cancer patients.
The literature shows that a decrease in depressive symptoms is indicative of better
survival. Antidepressants do improve depressive symptoms; however, the use of certain SSRIs in
treating depression in tamoxifen users may not improve survival due to negative drug
interactions. Only one study examined antidepressant use in those with depressive symptoms and
indicated that any positive effect would be seen over time and not immediately in cancer patients.
No study has examined the effect of antidepressant use on survival in the depressed breast cancer
population.
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2.4.3 The impact of depression treatment on direct medical cost
Table 2.6 summarizes the three studies that examine the association between direct
medical cost and depression treatment. All studies observed group therapy as a treatment for
depression.
Two studies looked at group therapy only and found no significant increase in cost for
this intervention83, 99. Simpson’s study indicated that the intervention significantly reduces cost
for those who have high medical expenses; however, this was not in the depressed breast cancer
population99 . Lemieux’s study indicated a non-significant reduction in cost for those who are
distressed at baseline and took part in group therapy83. These studies were both in the Canadian
breast cancer population and were not in the depressed population.
A U.K. study by Strong examined the cost of group therapy and indicated cost of
antidepressant use as part of this intervention for depressed cancer patients100. The average total
cost of the intervention was £334.86 ($670) per 6 months, which included antidepressant cost.
Antidepressant costs were £70.11(~$140) vs £20.79(~$42) for those in group therapy or not,
respectively. The difference is likely due to those in group therapy being more diligent in taking
antidepressants compared to those who are not in group therapy. This is the only study to
indicate cost of antidepressant use in depressed breast cancer patients. The results indicate that
antidepressant users would not have significantly increased costs in the depressed population. A
direct estimate of antidepressant cost in the United States cannot be made from this paper due to
differing pricing policies in the U.K. versus the United States.
The literature for cancer and depression treatment is sparse and focuses on group therapy.
There is an indication that antidepressant use would not significantly increase cost, and
potentially reduce direct medical cost in the depressed population. There is no study in the
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United States that has determined the effect of antidepressant use on direct medical cost in the
depressed breast cancer population.
2.4.4 Summary of Antidepressant use in the Depressed Breast Cancer Population
The literature examining the impact of treating depression (group therapy or
antidepressant) on adherence, survival and cost is sparse and focuses on those with depressive
symptoms instead of those with a diagnosis of depression. Studies examining the impact of
antidepressants on adherence do not account for a depression diagnosis or are in those with mild
depressive symptoms. These studies indicate that antidepressants potentially increase adherence
to hormone therapy in depressed breast cancer patients. Studies show that antidepressant use has
mixed results with survival in breast cancer; however, they were not in the depressed population
and only focused on one class of antidepressants. Treating depression improves survival, but no
study has looked at all antidepressants and their effect in the depressed population.
Antidepressant users would likely incur a non-significant increase in direct medical cost
compared to non- users; however, the study was in a U.K. population, who have differing pricing
policies compared to those in the United States. No study has determined the effect of
antidepressant use on direct medical cost in the depressed breast cancer population.

2.5 Overall Summary

Depression negatively affects hormone therapy adherence, survival and cost in breast
cancer patients. The studies that indicate a positive association of depression with adherence to
hormone therapy are in a unique population and do not take into consideration increased
monitoring by physicians due to a diagnosis of depression. Studies that indicate a negative
association of depression with adherence to hormone therapy used electronic monitoring and pill
counts to measure hormone therapy adherence only looked a prior diagnosis of depression and a
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single measure of adherence. No study has used a repeated measures analysis to determine the
effect of concurrent depression on adherence to hormone therapy in breast cancer. The literature
suggests that a history of depression negatively effects survival; however, only one study has
examined the effect of concurrent depression with survival and it was not in a United States
population. No study in the United States has examined the effect of concurrent depression on
survival in breast cancer patients. Depression increases cost in breast cancer; however, the
incremental cost of depression in these patients has not been reported. Literature that examined
the impact of antidepressant use on adherence, survival and cost in the depressed breast cancer
population is sparse. The literature indicates that treating depression may improve adherence and
survival but increase cost. The effect of antidepressant use on direct medical cost in the
depressed population is unknown. There are three questions from this literature review: 1) is
adherence to hormone therapy improved in the depressed population that uses antidepressants? 2)
is survival improved in the depressed population that uses antidepressants? 3) what is the impact
of antidepressant use in those with a diagnosis of depression on cost?

2.6 Specific Aims and Hypotheses

This study has three aims:
1) To explore the association of depression and antidepressant use with hormone therapy
adherence in hormone receptor positive breast cancer patients
H1A: Breast cancer patients with depression will have lower adherence to
hormone therapy then those without depression.
H1B: Breast cancer patients with depression and taking antidepressants will have
improved adherence to hormone therapy then those with depression not taking
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antidepressants
2) To explore the association of depression and antidepressant use with survival in hormone
receptor positive breast cancer patients
H2A: Breast cancer patients with depression will have a shorter survival time
compared to those without depression
H2B: Breast cancer patients with depression and taking antidepressant will have
increased survival compared to those with depression and not taking
antidepressants
3) To explore the association of depression and antidepressant use on direct medical cost in
hormone receptor positive breast cancer population
H3A: Breast cancer patients with depression will have increased cost compared
to those without depression
H3B: Breast cancer patients with depression and taking antidepressants will have
reduced direct medical cost compared to those with depression and not taking
antidepressants
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Table 2.1: Studies Examining the Association of Depression and Adherence to Hormone Therapy
Author
(year)
Ziller
(2008)

Data source

Outcome
Measure
Adherence

Sample
Size
89

French National
Health
Insurance
System
Hadji
Disease
(2013)
Analyzer
Database (IMS
Health) in
Germany
Kostev
Disease
(2014)
Analyzer
Database (IMS
Health) in
Germany
Grunfeld Guy's Hospital
(2005)
Breast Clinic
database
Aiello
COMBO study
Bowles
(2012)

Compliance
and persistence

288

Treatment
discontinuation
within 3 years

12,412

Bender
(2014)

Comprehensive
Breast Program
in Pittsburgh

Adherence

91

Kemp
(2014)

linked data from
45 and up study
to various
claims

Time to
discontinuation
of therapy

1,531

Clinic
information
from Marburg
Germany

Huiart
(2012)

Relevant Results
Depression has a nonsignificant increase in
adherence in tamoxifen group
and non- significant decrease
in adherence in AI group
A CES-D score of 23+
associated with non significant decrease in risk of
non- persistence
Depression associated with a
significant decrease in risk of
discontinuing therapy

Discontinuation 6,626
of treatment

Depression associated with a
significant decrease in the risk
of discontinuing therapy

Adherence

Depression not significantly
associated with adherence

110

Discontinuation 538
and duration of
therapy

Depression or mood changed
associated with nonsignificant increase in the
odds of discontinuing therapy
A higher Beck score at
baseline associated with
significant decrease in
adherence
Pre-existing depression
associated with non significant increase in the risk
of discontinuing therapy in
unadjusted and adjusted
models
New depression associated
with significant increase in
the risk of discontinuing
therapy in unadjusted model
for initial therapy
New depression associated
with non- significant increase
in the risk of discontinuing
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Author
(year)

Data source

Outcome
Measure

Sample
Size

Klepin
(2014)

Co-STAR
cohort from
STAR trial

Adherence

1,479

33

Relevant Results
therapy in adjusted models
A higher GDS score
associated with a significant
increase in the odds of nonadherence

Table 2.2: Studies Examining the Association of Depression and Survival

Data source
Onitilo
(2006)

Hjerl
(2003)

NHANES 1

Danish Breast
Cancer
Cooperation
Group

Vodermaier Prospective
(2014)
Canadian study

Goodwin
(2004)

SEER

Outcome
Measure
All- cause
mortality

Sample
Size
10,025

All- cause,
natural and
unnatural
mortality

20,593

All -cause and
breast cancer
specific
mortality

3 year hazard of
death
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1,646

19,645

Relevant Results
Those with cancer and
depression have a
significantly higher risk of
dying compared to those
without cancer or depression
In breast cancer, there is a
non- significant increase in
the risk of dying in the
depressed group compared
to non- depressed
Depression before surgery is
associated with an increased
risk of death
Depression after surgery is
associated with increased
risk of death in early stage
cancer patients but a nonsignificant decrease in late
stage
Those with depression have
a slightly significant
increase in the risk of all cause mortality and a nonsignificant increase in breast
cancer specific mortality
Depression is significantly
associated with an increased
risk of mortality in early
stage patients
Depression significantly
increased 3 year hazard of
death

Table 2.3: Studies Examining the Association of Depression and Cost

Author
(year)
Bambauer
(2007)

Data
source
MCBS

Pan
(2015)

MEPS

Jayadevappa SEER(2012)
Medicare

Jeffery
(2012)
Jancin
(2014)

Military
Data
Repository
News
report of
Jeffery talk

Outcome
Measure
Cost related
nonadherence
Total health
care
expenditures

Direct
medical cost

Sample Relevant Results
Size
13,835 Those with cancer and depression
had significantly higher cost related
non-adherence
4,766
Cancer patients with depression have
higher unadjusted expenditures

50,147

Total cost to
DoD

11,014

Total cost to
DoD

2,851
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Cancer patients with depression have
significantly higher total and
prescription cost after adjusting for
various characteristics
Men with depression during
treatment of prostate cancer have
significantly higher cost all around
Men with depression during or after
treatment of prostate cancer have
significantly higher long term cost
Cancer patients with depression had
lower unadjusted total cost but
higher mean per patient cost
Breast cancer patients with
depression have twice the unadjusted
cost as those without depression

Table 2.4: Studies Examining the Association of Depression Treatment and Adherence to
Hormone Therapy

Author
(year)
Navari
(2007)

Data source

Cluze
(2011)

Cohort
Elippse 40
study

Clinical trial

Trabulsi MED-ECHO
(2014)
databases

Outcome
Measure
Completion
of treatment
at 6 months

Sample
Size
193

Tamoxifen
interruption

161

Medication
adherence to
antiestrogen
therapy

4,715
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Relevant Results
Mildly depressed breast cancer
patients on the antidepressant
fluoxetine showed significantly
higher 6 month completion of any
cancer treatment
Tamoxifen patients on
antidepressants had a nonsignificant increase in the odds of
interruption
Those on antidepressants showed a
significant reduction in adherence to
antiestrogen therapy in breast
cancer

Table 2.5: Studies Examining the Association of Depression Treatment and Survival

Author
(year)
Kelly
(2010)

Data source

Outcome
Measure
Breast
specific and
all- cause
mortality

Sample
Size
24,430

Weaver
(2013)

NC Medicaidcancer registry

Cancer
related death

857

Fisch
(2003)

Hoosier Oncology
group

All- cause
mortality

129

Survival

235

linked prescription
drugs and cancer
registry in Ontario

Goodwin RCT in Canada
(2001)

Kissane
(2007)

GieseDavis
(2011)

Australian
Hospital data

RCT in California

Survival

All- cause
mortality

Relevant Results
Paroxetine showed
significantly increased hazard
of death from breast cancer
and all causes
Other antidepressants showed
a non- significant increase or
decrease in hazard of death
from breast cancer and all
causes
Using a CYP2D6 inhibitor
(antidepressant etc.) is
associated with a nonsignificant decrease risk of
death
Those with depressive
symptoms and taking
fluoxetine show a nonsignificant decrease in survival
compared to placebo
Breast cancer patients in group
therapy show no difference in
survival

227

Group therapy did reduce
depressive symptoms
Breast cancer patients in group
therapy show no difference in
survival

101

Group therapy did reduce
cases of depression
An increasing depressive score
(CES-D) is associated with an
increased risk of death
A decreasing depressive score
is associated with improved
survival
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Table 2.6: Studies Examining the Association of Depression Treatment and Cost

Author
(year)
Strong
(2008)

Data source
UK RCT

Outcome
Measure
Health care
cost

Sample
Size
200

Intervention
cost
Lemieux Breast Expressive
(2006)
Supportive
Therapy study

Simpson
(2001)

RCT in Canada

Direct
health care
cost

125

Billed cost

89

Relevant Results
Average direct cost of
intervention was $523
Those in group therapy for
depression had slightly higher
cost
Intervention of therapy had a
non- significant higher cost
If patient distressed at baseline
then therapy had a non significant lower cost
No difference between therapy
and control for mean billed cost
Therapy group had significantly
lower billed cost for those in the
upper quartile of billed cost
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CHAPTER 3 METHODS
3.1 Introduction

This chapter will describe the methods used to determine the final sample, define the
main independent and dependent variables, and covariates and describe the type of analyses used
for this study. Details on the data source, sample selection, variable operationalization,
confounders and analysis are covered in this chapter. This is a retrospective cohort design and an
explanation of this design and its application to this study will be discussed in this chapter.

3.2 Data source

The merged SEER-Medicare data set was used for this study. SEER-Medicare is a
comprehensive data set that is comprised of the SEER cancer registry and Medicare Claims.
The Surveillance Epidemiology and End Results program (SEER) is a comprehensive cancer
registry for the United States that started in 1973. SEER collects detailed information on incident
cancer cases, which includes primary tumor site, stage, first course of treatment and vital status.
SEER also routinely collects detailed demographic information for these incident cancer cases.
SEER currently covers ~30% of the United States population in all geographic region and the
data is used in calculating population rates (survival, incidence etc) for the United States101.
Medicare is a federal health insurance program for those who are 65 and older or those
with end stage renal disease or other disabilities. Medicare claims include Part A, Part B and Part
D claims. Medicare patients have the option of enrolling in Parts A and B (government
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insurance) or in Part C (HMO, private insurance). Part A claims consist of inpatient hospital
claims and Part B claims consist of outpatient hospital claims and physician visit claims. Parts
and B have claims information starting in 1991. Part A and B claim information includes cost of
the claim to Medicare, procedure performed, diagnosis for procedure and the date of the claim.
Part D is prescription drug coverage that contains drug claims since July 2006. Part D claim
information includes the date of dispensing the drug, generic and brand name of the drug, and the
days supplied.
SEER data was merged with Medicare claims using last name and social security number
by CMS and the final data de-identified. The merged dataset is considered representative of the
United States population. The final dataset contained unique patient identifiers to link between
SEER data and Medicare claims101. The data was provided in four files: SEER, Part A, Part B
and Part D. SEER-Medicare data for 2005-2010 was used for this study.

3.3 Study Design

This is a retrospective cohort design. Patient information was collected one year prior to
and up to four years after breast cancer diagnosis. This design is used because this study uses
previously collected information and follows a past cohort of breast cancer patients (2006-2009),
from a specific point in time, date of diagnosis, forward to the most current time available102.
Based off previous studies, the conceptual framework uses identified socio-demographic
and clinical factors that are related to depression in breast cancer patients. These factors are
income, stage at diagnosis, treatment (radiation, chemotherapy, type of surgery), comorbidities,
marital status, age, race and type of hormone therapy used103, 104. In order to determine the
association of depression, these factors are adjusted for in the analysis.
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3.3.1 Sample Flow Chart
The following chart represents the populations of this study to answer the main hypotheses.

All Breast Cancer

Hormone Receptor
Postive Breast Cancer

***Starting hormone
therapy within a year

**Depressed

*Antidepressant Use

**Non Depressed

*No Antidepressant
Use

Figure 3.1: Sample Selection Framework
The groups with asterisks beside them are the populations of interest for this study. The
primary study population has three asterisks beside it. The populations with two asterisks were
used to test the hypotheses that depression reduces adherence to hormone therapy, and survival
and increases cost. The populations with one asterisk were used to test the hypotheses that those
with depression and taking antidepressants have decreased cost and improved survival and
adherence to hormone therapy compared to those with depression and not taking antidepressants.
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3.4 Sample selection

3.4.1 Initial breast cancer population
The breast cancer population was identified from the SEER registry using the provided
cancer site code for breast cancer (46) for those diagnosed from 2006-2009. Estrogen and
progesterone receptor status was determined from the registry using provided indicator variables
for these biomarkers. Those with known estrogen or progesterone receptor positive status were
included in the final sample. Of these patients, those with non- metastatic breast cancer and who
were at least 65 at diagnosis were kept for analysis. Metastatic status was determined using the
7th edition of the AJCC breast cancer staging system of those with stage IV were considered
metastatic105. Age was determined by a provided recode variable that indicated an age group at
diagnosis. The included age groups were 65-69,70-74, 75-79, 80-84 and 85+. Of these patients,
only those on hormone therapy were included.
3.4.2 Hormone therapy use
Hormone therapy was determined by a SERM or AI claim in Medicare Part D within a
year of cancer diagnosis. SERMS and AIs were identified using the brand name of the drug. For
example, a claim of arimidex for patients taking anastrozole. A frequency of brand names was
done and matched with hormone therapy agents presented by breastcancer.org and the Susan G
Komen website. Patients with hormone receptor positive breast cancer starting hormone therapy
within a year were followed in Medicare for a minimum of 1 year and up to 4 years. Hormone
therapy was classified as SERM only or aromatase only. Those who had claims for both were
excluded.
3.4.3 Final sample for analysis
The final sample included only those who were continuously enrolled in part A and part
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B from 1 year prior to cancer diagnosis through year post cancer diagnosis. The sample was
restricted to those who were not enrolled in an HMO at all during this time- period as HMO’s are
private insurers, and those enrolled in an HMO will not have available information during this
time. This requirement was to determine co-morbidities 1 year prior to the cancer diagnosis and
to determine depression up to a year post diagnosis. Women with a diagnosis for schizophrenia,
295.xx, or bipolar disorders,(296.xx) excluding 296.2 and 296.3, or those with any antipsychotic
medication claim during the year before cancer diagnosis were excluded from the study. Those
with unknown stage or grade were also excluded from the final sample.

3.5 Primary independent variables

3.5.1 Depression
Patients with ICD-9 codes 311, 296.2, 296.3, and 300.4 from a hospital or physician
claim were classified as being depressed. To be included in the depressed population, a patient
had at least one claim within a year after cancer diagnosis. Depression was classified as either
yes or no. Those with a depression claim within a year before cancer diagnosis were considered
to have a history of depression.
3.5.2 Antidepressant Use
Antidepressant use was identified using drug name in part D claims. Antidepressants
were classified as a selective serotonin reuptake inhibitor (SSRI), SNRI, TCA or miscellaneous.
Depressed breast cancer patients on antidepressants had to have at least one antidepressant claim
after their depression diagnosis to be included in the analyses to determine the effect of
antidepressant use on cost, survival and adherence to hormone therapy.
To distinguish between those who used antidepressants consistently or not, a variable
indicating the number of 30-day supply fills for an antidepressant was included. Those with more
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than a 30-day supply were counted in intervals of 30 based of their supply. For example, a person
with a 60-day supply would have a count of two for that claim.
Continuous antidepressant use was categorized as those who continuously used an
antidepressant for less than 90, 90, 180 or 365+ days.

3.6 Primary Dependent Variables

3.6.1 Adherence to hormone therapy
Hormone therapy adherence rate was determined using the percent days covered (PDC)
for the duration of medication use by a breast cancer patient22. Adherence was measured for up
to 4 years of therapy. Adherence was measured on a quarter (90 days) by quarter basis until not
continuously enrolled in part D or end of study. Using this method, PDC = (days covered)/
(duration of medication use). The duration of medication use is calculated from the start of
hormone therapy to the end of the indicated quarter. This is equivalent to 90 multiplied by the
quarter number. For example, the duration of medication use for the third quarter is 270, 90*3.
The quarter number increases each quarter, so the sixth quarter represents one and half years on
hormone therapy. In each interval, those classified as adherent had a PDC≥ 80% in order to be
consistent with published literature on hormone therapy adherence22, 36, 51. Adherence was
measured while the patient was continuously enrolled in part D and was stopped if the patient was
no longer enrolled in part D. This restriction was applied to ensure complete information was
available to measure adherence to hormone therapy. If a person was not enrolled in Part D, a
refill might not be captured and a person who would be classified as adherent would be classified
as non-adherent.
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3.6.2 Persistence
A breast cancer patient with a gap of 90 or more days between the end of their last supply
and their next fill date for hormone therapy was classified as non-persistent19, 33, 90. This time
frame was chosen to be consistent with published literature.
3.6.3 Cost
Total direct medical cost was calculated as the sum of pharmacy, physician and hospital
cost for provided services per patient per year from cancer diagnosis. Cost was from the payer’s
perspective (Medicare’s), and was the amount paid for services or drugs by Medicare. Cost was
inflation adjusted to 2010 U.S. dollars using the Consumer Price Index inflation calculator106.
The analysis used accounts for the skewed nature of cost and further details are in the analysis
section.
3.6.4 Survival
Survival was determined from the cancer registry and was measured in months from
cancer diagnosis until death or December 31, 2012, which is the last day the registry has
information on these patients. This is a longer follow up time as the registry reports this
information instead of using available claims for cost and adherence to hormone therapy.

3.7 Additional covariates

Patient co-morbidity was measured using the Charlson co-morbidity score a year before
their breast cancer diagnosis. ICD-9 codes were used to determine patients’ co-morbidity score
with a higher score indicating more severe co-morbidities107. Co-morbidity scores were classified
as 0, 1 or 2+23. Age, race, geographic location and median income of zip code were used to
account for socio-demographic status for a person. Age at the time of breast cancer diagnosis
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was categorized as 65-69, 70-74, 75-79, 80-84 and 85+. Race was categorized as white, black or
other108. Geographic location was determined by two variables. The first indicated urban setting
or not. The second indicated SEER location, classified as northeast, north central, west and north
central as defined by SEER109. The median income of the zip code was classified as under $30K,
between $30K and $50K, and over $50K previously defined in work done with SEERMedicare11. Those with unknown income were not included. Cancer stage and grade were also
included to account for cancer severity. Cancer stage and grade were categorical variables.

3.8 Analysis

Descriptive statistics were used to illustrate sample characteristics and differences
between those with depression and those without depression. These statistics were also used to
characterize antidepressant users and non- users in the depressed population. Chi-square statistics
were used to compare categorical variables across groups and the two-sample t-test was used to
compare continuous variables across groups. For all regression models, an a priori selection of
variables based off the conceptual framework were used. To test the hypothesis that those with
antidepressant use will have improved adherence to hormone therapy in the depressed population,
a generalized linear regression with logit-link and binomial distribution for repeated measures
was used. This analysis is similar to logistic regression and does yield odds ratios from the
parameter estimates. A generalized linear regression with log-link and gamma distribution for
repeated measures of total cost was used to test the hypothesis that those on antidepressants will
incur lower cost in the depressed population and to determine the incremental cost of depression.
Kaplan Meier estimates were used to determine the initial association of depression and
antidepressant use in the depressed population with persistence and survival. Kaplan-Meier
estimates and a time interaction variable in the cox proportional hazards model were used to test
the proportional hazards assumption. If proportional hazards were indicated (curves did not cross
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and the interaction variable was not statistically significant), the association of depression and
antidepressant use in the depressed population was reported from the adjusted Cox proportional
hazards model. If proportional hazards were not indicated, (curves did cross and the time
interaction variable was statistically significant), the distribution was determined using a linear
survival model that fits different distributions. The distribution with the best fit (lowest AIC
value) was used to estimate the association of depression and antidepressant use in the depressed
population, adjusting for clinical and demographic characteristics.
The following model is the general form used for the analysis for the association of
depression with adherence to hormone therapy. Y indicates the probability of adhering to
hormone therapy so e^β is the adjusted odds ratio for the parameter110, 111. For this study, e^ β1 is
the estimate of interest as it indicates the odds of adhering to hormone therapy if a person has
depression adjusting for demographic and clinical characteristics110.
Log (Y/1-Y) = β1 *depression + β2 * age + β3 *race + β4 *co-morbidity + β5 *SEER site + β6
*urban + β7 *cancer stage + β8 *chemotherapy + β9 *radiation+ β10 *cancer grade + β11 *history of
depression + β12 *count indicating repeated measures

The following model is the general form used for the analysis for the association of
depression with survival. Hi represents an individual’s hazard of death and t indicates length of
time a person survives. H0 is the baseline hazard function. No assumption is needed for the
baseline hazard function when there are proportional hazards between groups and H0 is not in the
model. If proportional hazards are not indicated, then H0 is in the model as a baseline hazard
function for the sample. For this study, e^(β1) is the estimate of interest as it indicates the risk of
death if a person has depression adjusting for demographic and clinical characteristics112.
Hi(t) = H0 * (e^(β1 *depression + β2 * age + β3 *race + β4 *co-morbidity + β5 *SEER site + β6
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*urban + β7 *cancer stage + β8 *chemotherapy + β9 *radiation+ β10 *cancer grade + β11 *history of
depression) )
The following model is the general form used for the analysis for the association of
depression with cost. Y represents total cost per patient per year and Log (E(Y|variable)) is the
log cost based off the log link used for this association. For this study, β1 is the estimate of
interest as it indicates the increase in cost a person has depression adjusting for demographic and
clinical characteristics113. The intercept in this case is baseline cost for the sample and estimates
are added to the intercept for the total cost94.
Log (E(Y|variable)) = intercept+ β1 *depression + β2 * age + β3 *race + β4 *co-morbidity + β5
*SEER site + β6 *urban + β7 *cancer stage + β8 *chemotherapy + β9 *radiation+ β10 *cancer grade
+ β11 *history of depression + β12 *count indicating repeated measures

The following model is the general form used for the analysis for the association of
antidepressants with adherence to hormone therapy in the depressed population. Y indicates the
probability of adhering to hormone therapy so e^β is the adjusted odds ratio for the parameter110,
. For this study, e^ (β1 is the estimate of interest as it indicates the odds of adhering to hormone

111

therapy if a person has depression adjusting for demographic and clinical characteristics.
Log(Y/1-Y) = β1 *antidepressants + β2 * age + β3 *race + β4 *co-morbidity + β5 *SEER site + β6
*urban + β7 *cancer stage + β8 *chemotherapy + β9 *radiation+ β10 *cancer grade + β11 *history of
depression + β12 * number of 30 day antidepressant supplies + β13 * count indicating repeated
measures
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The following model is the general form used for the analysis to determine the
association of antidepressants with survival in the depressed population. Hi represents an
individual’s hazard of death and t indicates length of time a person survives. H0 is the baseline
hazard function. No assumption is needed for the baseline hazard function when there are
proportional hazards between groups and H0 is not in the model. If proportional hazards are not
indicated, then H0 is in the model as a baseline hazard function for the sample. For this study,
e^(β1) is the estimate of interest as it indicates the risk of death if a person with depression uses
antidepressant adjusting for demographic and clinical characteristics112.
Hi = H0 * e^( β1 *antidepressants + β2 * age + β3 *race + β4 *co-morbidity + β5 *SEER site + β6
*urban + β7 *cancer stage + β8 *chemotherapy + β9 *radiation+ β10 *cancer grade + β11 *history of
depression + β12 * number of 30 day antidepressant supplies)
The following model is the general form used for the analysis to determine the
association of antidepressants with cost in the depressed population. Y represents cost and Log
(E(Y|variable)) is the log cost based off the log link used for this association. For this study, β 1 is
the estimate of interest as it indicates the increase in cost a person with depression uses
antidepressants adjusting for demographic and clinical characteristics113. The intercept in this
case is baseline cost for the sample and estimates are added to the intercept for the total cost 94.
Log (E(Y|variable)) = intercept+ β1 *antidepressants + β2 * age + β3 *race + β4 *co-morbidity +
β5 *SEER site + β6 *urban + β7 *cancer stage + β8 *chemotherapy + β9 *radiation+ β10 *cancer
grade + β11 *history of depression + β12 * number of 30 day antidepressant supplies + + β13 *
count indicating repeated measures
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CHAPTER 4 RESULTS
4.1 Overview

This chapter begins with a description of breast cancer patients with and without a
diagnosis of depression followed by a description of those breast cancer patients with depression
who use antidepressants and those who do not. Results related to hypotheses H1A-H3B will
follow and addressed separately. For each hypothesis, the association of depression is estimated
followed by the test of the hypothesis. A concluding statement indicates if the results support the
indicated hypothesis. Results are presented in the following order: 1) the association of
depression and antidepressant use with adherence to hormone therapy 2) the association of
depression and antidepressant use with survival and 3) the association of depression and
antidepressant use with cost in breast cancer patients.
The hypotheses to be tested are:
H1A: Breast cancer patients with depression will have lower adherence to
hormone therapy then those without depression.
H1B: Breast cancer patients with depression and taking antidepressants will have
improved adherence to hormone therapy then those with depression not taking
antidepressants
H2A: Breast cancer patients with depression will have a shorter survival time
compared to those without depression
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H2B: Breast cancer patients with depression and taking antidepressant will have
increased survival compared to those with depression and not taking
antidepressants
H3A: Breast cancer patients with depression will have increased cost compared
to those without depression
H3B: Breast cancer patients with depression and taking antidepressants will have
reduced direct medical cost compared to those with depression and not taking
antidepressants

4.2 Baseline Characteristics
The SEER registry included 147,081 women with breast cancer satisfying the preliminary
inclusion criteria. The majority (72%) had a diagnosis of hormone receptor positive cancer.
After restricting the population to those 65 and older, not diagnosed at autopsy, not enrolled in an
HMO and took hormone therapy within a year of cancer diagnosis, 10,471 were further identified
as depressed (N=1,073) or not depressed (N=9,398) (figure 4.1). The enrollment and metastatic
restriction is where the most patients were lost in the final selection for the sample population
(figure 4.1). Of the 10,471 hormone receptor positive breast cancer patients taking hormone
therapy, 8,522 (81%) took an AI and 1,949 (19%) took a SERM. The depressed population made
up 10% of the final study sample, which is consistent with the 7% found in Goodwin's study in
the general SEER-Medicare breast cancer population54. The depressed population differed
significant from the non-depressed population on several factors. These include a history of
depression, more co-morbidities, and more severe cancer (table 4.1). Consistent with more
advanced cancer is the choice of a mastectomy, an invasive procedure, compared to breast
conserving surgery. Consistent with Goodwin, those who are not married and white are more
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prevalent in the depressed population. Those with radiation treatment are significantly fewer in
the depressed population (table 4.1).
Of the 1,073 depressed patients, 664 (62%) had an antidepressant claim after their diagnosis of
depression. For antidepressant users, 339 (51%) took an SSRI, 94 (14%) took an SNRI. 56 (8%)
took a TCA and 175 (26%) took a different antidepressant. Those taking antidepressants had
more history of depression, lower grade cancers, and were younger (table 4.2). No other
significant differences were observed between antidepressant users and non-users.

4.3 Adherence to Hormone Therapy

4.3.1 Association of Depression with Adherence to Hormone Therapy
For reference, this section is testing hypothesis H1A: Breast cancer patients with
depression will have lower adherence to hormone therapy then those without depression.
Consistent with previous studies, the number of patients who stayed adherent to hormone
therapy reduced over time (figure 4.2). Table A.1 presents the number of patients observed in
each quarter. Fewer patients (statistically significant) adhered to hormone therapy in the
depressed group compared to the non-depressed group (figure 4.2). Depressed patients had
significantly lower PDC values compared to the non-depressed group (table 4.3). Of note, the
difference in mean PDC values between the depressed and non-depressed group consistently
increased over the length of time a patient was on hormone therapy. In the GLM with a logit link
and binomial distribution (test of H1A), depression was associated with a 19% reduction (p<0.01)
in the odds of adhering to hormone therapy after adjusting for various clinical and demographic
variables (table 4.4). Those with a history of depression had a 15% reduction (p<0.01) in the
odds of adhering to hormone therapy. The repeated measures variable indicating the number of
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measures a person had was associated with a 9% reduction (p<0.0001) in the odds of adhering to
hormone therapy. Other factors that were significantly associated with reduced odds of adhering
to hormone therapy were AI use, in a Midwest or South SEER site, and age>74 and in an urban
area. Factors that were significantly associated with increased odds of adhering to hormone
therapy were a mastectomy and a race that was neither black nor white.
Adherence to hormone therapy does reduce over time, which is shown in unadjusted
counts and mean PDC values for each quarter and in the adjusted GLM model. Those with
depression consistently have reduced adherence to hormone therapy over time, which is reflected
in both unadjusted count and mean PDC values for each quarter. The unadjusted values and the
adjusted value from the GLM model provide support for hypothesis H1A that patients with
depression do have reduced adherence compared to those who do not have depression.
4.3.2 Association of Antidepressants with Adherence to Hormone Therapy
For reference, the hypothesis tested in this section is H1B: Breast cancer patients with
depression and taking antidepressants will have improved adherence to hormone therapy then
those with depression not taking antidepressants
The sample size for the test of hypothesis H1B is in table A.2 and reflects the number of
patients analyzed in each quarter. In breast cancer patients with depression (depressed sample),
antidepressant users had higher PDC values compared to non-users, but the difference was not
statistically significant (table 4.5).
There was little difference in the percent of patients who were adherent to hormone
therapy between antidepressant users vs non-users for quarters 1-7. Antidepressant users were
consistently more adherent to hormone therapy compared to non-users starting at quarter 8 in the
depressed sample (figure 4.3). Antidepressant users had a significantly higher percentage of
patients who adhered to hormone therapy (55%) compared to non-users (45%). These results
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indicate that antidepressant use is associated with improved adherence to hormone therapy in the
depressed sample; however, this difference varies across the period of treatment.
To determine the association of antidepressant use with adherence to hormone therapy
(test of H1B), a GLM was used for repeated measures to adjust for confounders. After adjusting
for clinical and demographic characteristics, antidepressant use was associated with a nonsignificant 21% decrease in the odds of adhering to hormone therapy. The indicated negative
association potentially reflects the severity of depression, as those with more severe depression
are more likely to be on antidepressants. Figure 4.3 suggests that duration of antidepressant use is
an important factor to consider as a benefit was shown only after 8 quarters of hormone therapy
adherence measures. To account for the benefit of extended antidepressant use, patients were
classified by the length of time they continually used antidepressants (<90 days, 90-179 days,
180-364 days, 365+ days). In the GLM model, antidepressant users who continually took an
antidepressant for a year had a 340% increase in the odds of adhering to hormone therapy
(p<0.0001) compared to non-users (table 4.6). This marked increase in the probability of
adherence to hormone therapy indicates that those who are depressed and use antidepressants
benefit from long- term use of antidepressants.
Those on antidepressants have improved adherence over time in the depressed sample;
however, this benefit is seen for continual use of antidepressants over time. The results do not
fully support the stated hypothesis that breast cancer patients with depression and taking
antidepressants have better adherence compared to those not taking antidepressants.
4.3.3 Persistence to Hormone Therapy
Those with depression consistently had a significantly shorter time in persisting with
hormone therapy (median 23 months), compared to those without depression (median 27 months)
(figure 4.4). The proportional hazards assumption was met and the adjusted association of
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depression with persistence to hormone therapy was assessed with the Cox proportional hazards
model. Those with depression had a non-significant 106% increase in the risk of non-persistence
to hormone therapy adjusting for clinical and demographic characteristics. Those with a history
of depression had a 115% increase (p<0.05) in the risk of non-persistence to hormone therapy.
Other factors significantly associated with non-persistence to hormone therapy are charlson score
(2+), stage (2+), grade (3+), from a western SEER site, and age (85+). A mastectomy is the only
factor that is associated with a significantly reduced risk of non-persistence (7% reduction).
Those who have a history of depression have a significant increase in non-persistence
while those with concurrent depression have a non-significant increase in non-persistence. As the
majority of depressed patients also have a history of depression, this result could indicate that
chronic depression is the reason for non-persistence rather than newly diagnosed depression. A
condensed variable that combines history of depression with concurrent depression to reflect this
close association was considered; however, as the focus of this study is the association with
depression with and without a history of depression, the condensed variable was not used.
In the depressed population, those on antidepressants had increased time persisting with
hormone therapy (median 24 months) than those who did not take an antidepressant (median 21
months) (figure 4.5). Those who continually used antidepressants had increased persistence from
90 days of antidepressant use (median 24 months) to 1 year of antidepressant use (median 32
month) (figures 4.6-4.8). General antidepressant use was associated a non-significant 104%
increase in the risk of non-persistence to hormone therapy (table 4.8). Surprisingly, those who
used antidepressants continuously for 180 days had a significant 131% increase in the risk of nonpersistence. This could be due to side effects, inability to handle multiple medications over a
period of time or other reasons that are not able to be determined at this time. Those who
continually used antidepressants for a year showed a significant 45% reduction in the risk of nonpersistence to hormone therapy. This indicates that the length of time on antidepressants is
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critical for depressed patients to benefit from this therapy. Other factors significantly associated
with non-persistence are stage (3+), chemotherapy use and age (85+). No other factors were
significantly associated with persistence.
Persistence and adherence are connected, as those who are not persistent are not adherent.
The persistence to hormone therapy results reflect adherence to hormone therapy results:
depression reduces adherence to hormone therapy and persistence to hormone therapy, and
antidepressant use for a year improves adherence to hormone therapy and persistence to hormone
therapy in patients with depression. These results indicate that it is continual use of
antidepressants, not general use, which improves adherence to hormone therapy. The overall
results support hypothesis H1A (depression reduces adherence to hormone therapy) but do not
support hypothesis H1B (general antidepressant use improves adherence to hormone therapy).

4.4 Survival

4.4.1 Association of Depression with Survival
For reference, the hypothesis tested in this section is H2A: Breast cancer patients with
depression will have a shorter survival time compared to those without depression.
The depressed population had lower survival compared to the non-depressed population
(mean 57 months vs 63 months). The longer survival time reflects SEER data reported through
2012 for these patients instead of 2010 in the claims. Those in the depressed group always had
lower survival compared to the non-depressed group (figure 4.9). The proportional hazards
assumption was not met for this population. In order to adjust the association of depression with
survival for confounders, a test for the underlying distribution of the hazard function was done.
The underlying hazard distribution for this population was determined to be lognormal after
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testing potential distributions and choosing the best fit based off the lowest AIC value. A
parametric model using this underlying distribution was used to determine the adjusted
association of depression with survival. Those with depression had a 31% decrease in survival
after adjusting for clinical and demographic characteristics (p<0.05) (table 4.9). Those with a
history of depression had a non -significant 7% decrease in survival. This is not consistent with
Goodwin's finding for a history of depression and survival; however, Goodwin did not look at
concurrent depression or adjust for clinical factors. As the majority of those with depression also
have a history of depression, it is likely that Goodwin's result (HR= 1.42) is split between the two
variables in this analysis and any other difference is likely attributed to further adjustment for
clinical variables that decrease survival. Other factors associated with a significant decrease in
survival were Charlson score (1+), stage (1+), grade (2+), a southern SEER site, black, age (74+),
and income (30K+). Factors associated with a significant increase in survival time were having a
mastectomy, radiation therapy, a race other than white or black, in an urban area and married.
Concurrent depression significantly reduces survival in breast cancer patients and over
time those who are depressed are less likely to survive compared to those who are not depressed.
The results support hypothesis 2A stating depression does negatively affect survival.
4.4.2 Association of antidepressants with Survival
For reference, the hypothesis to be tested is H2B: Those with depression and taking
antidepressant will have increased survival compared to those with depression and not taking
antidepressants.
In the depressed sample, antidepressant use had a similar mean survival time (57 months)
compared to the non-users (56months). General antidepressant use did not have any effect on
survival in breast cancer patients with depression (figure 4.10). As previously determined, the
length of time antidepressants are used is a critical factor in determining a benefit for using them

57

in the depressed population. Antidepressants users for at least 90 days had a mean survival time
of 58 months and overlap with non-users, which reflects the original full antidepressant
population (figure 4.11). This indicates that 90 days is not enough time to gain any survival
benefit from taking antidepressants if depressed. Antidepressant users for under 90 days had a
mean survival time of 32 months and a marked drop in survival time after 10 months was
indicated in this population (figure 4.11). These results potentially indicate that if a depressed
person is going to use an antidepressant, they are better off not taking it than taking it for less than
90 days. The proportional hazards assumption was not met and further adjustment was done
using the underlying log normal distribution. After adjusting for confounders, 90 day
antidepressant users had a non -significant 151% increase in survival compared to antidepressant
users for less than 90 days. Antidepressant non-users had a non-significant 169% increase in
survival compared antidepressant users for under 90 days after adjusting for confounders (table
A.5). Antidepressant users for 180 days had a mean survival time of 60 months compared to 52
months for antidepressant non-users. Those who continuously used an antidepressant for 180
days always had a better survival time. As seen with the 90 -day users, antidepressant users for
less than 180 days had the worst survival (figure 4.12). Adjusted estimates were determined
using the underlying log normal distribution. In this model, antidepressant use for less than 180
days had a non- significant 18% decrease in survival compared to no antidepressant use adjusting
for confounders. Antidepressant use for 180 days had a non-significant 13% increase in survival
adjusting for confounders (table A.6). Antidepressant users for at least a year had a mean
survival time of 58 months compared to 56 months in antidepressant users under 1 year.
Antidepressant users for a year always had better survival replicating the 90 and 180-day results.
In this instance, non-users of antidepressants and non-continual users were similar to each other
(figure 4.13). Adjustment using the underlying log normal distribution model showed that those
who did not use antidepressants had a 55% decrease (p<0.05) in survival compared to those who
did use an antidepressant for a year. Those who did not use an antidepressant for a year had a
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60% reduction (p<0.05) in survival compared to those who did use an antidepressant for a year
adjusting for confounders (table A.7). Any benefit from using antidepressants for those with
depression likely occurs after the first 180 days of continuous use and the benefit appears to
increase as the length of time of use increases.
The results do not support hypothesis H2B (survival is improved with general
antidepressant use).

4.5 Cost

4.5.1 Unadjusted cost for those with Depression and those without Depression
For reference, the sample size for each year of cost is found in table A.3.
In the first year after breast cancer diagnosis, depressed patients had non-significant
lower median cost. In subsequent years patients with depression had higher median cost which
was statistically significant for years 2, 3 and 5 after cancer diagnosis (table 4.10). Over time,
cost in both groups went down, particularly from year 1 to year 2 after cancer diagnosis. Those
with depression might have lower cost in the first year due to not taking prescriptions or
following through with chemotherapy or radiation treatment. After the first year, those with
depression likely incur greater cost due to cancer recurrence (not taking hormone therapy or did
not receive chemotherapy etc.) or hospitalization due to depression or other reasons.
4.5.2 Association of Depression with all cost
For reference, the hypothesis tested in this section is H3A: Breast cancer patients with
depression will have increased cost compared to those without depression.
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A depression diagnosis was associated with a non- significant increase in per patient per
year cost after adjusting for clinical and demographic characteristics. Those with depression
incurred $230,960.04 (intercept + depression estimate) per patient per year cost compared to
$208,981.29 (intercept) for those without depression adjusting for clinical and demographic
characteristics. The incremental cost of depression was $21,978.75 (depression cost – nondepression cost, p>0.05) per person per year adjusting for clinical and demographic
characteristics (table 4.11). Surprisingly, depression did not significantly increase cost; however,
as the model adjusted for other co-morbidities and cancer severity this is not as surprising. Both
cancer stage and the comorbidity score significantly increased cost. Patients with depression do
have more comorbidities and more severe cancers, so their cost will be higher due to these
factors. It is likely that patients with depression already have doctor’s visits planned and do not
incur additional doctor’s visits because they have depression. In this case, the comorbidity score
and cancer stage variables capture these visits instead of the depression variable, which would
indicate why the $21,978.25 is not significant.
The stated results do not support hypothesis H3A that depression increases cost;
however, the estimate was positive and indicated an increase in cost for patients who have
depression.
4.5.3 Unadjusted cost in the depressed population for those using antidepressants and those not
using antidepressants
For reference, table A.4 indicates the sample size for each year for antidepressant users
and non-users in patients with depression.
Those who took antidepressants had non-significant higher median cost in the depressed
population in all years except year 2 after cancer diagnosis (table 4.12). In year 2, those on
antidepressants had significantly higher costs. As depression was diagnosed within a year of
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cancer diagnosis and antidepressant use was required to be after the depression diagnosis, the
significant increase in cost in year 2 probably reflects the initiation of antidepressants. As some
antidepressants are costly, the initiation is likely the reason for significantly higher cost. It is
possible that antidepressant use over time decreases medical cost but the magnitude is not
sufficient to offset the prescription cost of the antidepressant or potentially increased physician
visits to continue using antidepressants.
4.5.4 Association of antidepressants with all Cost
For reference, the tested hypothesis is H3B: Breast cancer patients with depression and
taking antidepressants will have reduced direct medical cost compared to those with depression
and not taking antidepressants
Antidepressant users did not have significantly increased cost after adjusting for clinical
and demographic characteristics (table 4.13). Antidepressant users incurred $178,082.11 per
patient per year compared to $150,241.61 adjusting for clinical and demographic characteristics.
The incremental cost for antidepressant use was $27,840.50. As mentioned earlier, these patients
are likely seeing a doctor and are not incurring significantly increased cost. In addition to a single
doctor’s visit covering multiple comorbidities and cancer severity, antidepressant use could also
keep patients out of the hospital and so would potentially reduce cost due to reduced hospital
visits. As antidepressants are expensive, it is likely that the reduced cost from fewer hospital
visits does not offset the increase in cost of the antidepressant. This balance would also explain
why the increased cost is not statistically significant. As the benefit of antidepressant use was
seen over time in previous results, the duration of antidepressant was taken into account in this
analysis. Those who continually used antidepressants for at least 90 days indicated reduced cost.
Cost were reduced more at 180 days of antidepressant use compared to the other categories with
an $11,551.12 (p>0.05) reduction. This non-significant decrease is likely indicative that the cost
of antidepressant use is greater than the benefit of reduced hospital visits or other medical
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complications. It is possible that depressed patients will see a greater reduction in cost for
continual use of antidepressants from their perspective.
For H3B, these results do indicate a potential reduction in cost for long- term
antidepressant use; however, this reduction was not significant. The results indicate that H3B
(cost is reduced with general antidepressant use) is not supported. It is possible that a cost utility
study in this population will show that the extra cost of antidepressant use is worth the additional
quality adjusted life years gained from antidepressant use.

4.6 Summary
The presented results established that those with depression have reduced adherence to
hormone therapy, reduced survival and increased cost. These results also establish that treating
the depressed population with antidepressants for at least 180 days improves adherence to
hormone therapy and improves survival. From Medicare’s perspective, long-term antidepressant
might reduce cost over several years; however, it is likely that antidepressant use is a cost
effective treatment for depressed breast cancer patients.
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147,081 Female breast
cancer patients
identified from SEER
Initial population

105,855 with hormone
receptor positive breast
cancer
Dropped those who were diagnosed at autopsy, metastatic,not continuously enrolled in part A and B 1 year prior through
1 year post diagnosis or part of an HMO in these years

10,471 with hormone
therapy within a year
and 65+

9,398 do not
have depression
within a year of
diagnosis

1,073 have depression
within a year of
diagnosis

409 did not use an
antidepressant after
depression diagnosis

664 did use an
antidepressant after
depression diagnosis

Figure 4.1 Sample Selection
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Differences are significant for depressed and non-depressed
Differences are significant for
depressed and non-depressed
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Figure 4.2 Percent of Patients Adherent to Hormone Therapy Over Time in the Depressed
and Non-Depressed Population: Percent patients who are adherent to hormone therapy by
quarter from start of hormone therapy in the depressed and non-depressed populations.
Chi-square analysis was used to determine significant differences between those with
depression and no depression by quarter.
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Figure 4.3 Adherence in Antidepressant Users and Non-Users in the Depressed
population: * indicates significant difference from chi-square analysis between users and
non-users by quarter
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No Depression

Depression

Figure 4.4 Persistence in the Depressed and Non-Depressed Population: Kaplan-Meier
estimates for time of persisting with hormone therapy
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Antidepressant Use

No Antidepressant Use

Figure 4.5 Time to Non-persistence for Antidepressant Users and Non-Users in the
Depressed Population: Kaplan-Meier estimates for persistence in antidepressant users and
non-users in the depressed population
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90+ Day Antidepressant Use

No
Antidepressant

< 90 day Antidepressant Use

Figure 4.6: Time to Non-persistence of Hormone Therapy in the Depressed Population
for Antidepressant users for 90+ days: Kaplan-Meier estimates for persistence in
antidepressant users for at least 90 days, less than 90 days and non-users in the depressed
population
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180+ Day Antidepressant
Use

< 180 day
Antidepressant Use

No Antidepressant

Figure 4.7: Time to Non-persistence of Hormone Therapy in the Depressed Population
for Antidepressant users for180+ days: Kaplan-Meier estimates for persistence in
antidepressant users for at least 180 days, less than 180 days and non-users in the
depressed population
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1+ Year Antidepressant Use

<1 Year Antidepressant Use

No Antidepressant

Figure 4.8: Time to Non-persistence of Hormone Therapy in the Depressed Population
for Antidepressant Users for at least 1 Year: Kaplan-Meier estimates for persistence in
antidepressant users for at least 1 year, less than 1 year and non-users in the depressed
population
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Depressed population

Non- depressed population

Figure 4.9 Survival in the Depressed and Non-Depressed Populations: Kaplan-Meier
estimates for months survived since breast cancer diagnosis in the depressed and nondepressed populations
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No antidepressant
Antidepressant

Figure 4.10 Survival for Antidepressant Users and Non-Users in the Depressed
Population: Kaplan-Meier estimates for months survived since breast cancer diagnosis in
the depressed population for those on antidepressants or not on antidepressants.
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90+ Day Antidepressant Use

No
Antidepressant

<90 day Antidepressant Use

Figure 4.11 Survival in the Depressed Population for Those Who Continuously Use
Antidepressants for 90 Days: Kaplan-Meier estimates for months survived since breast
cancer diagnosis in antidepressant users for at least 90 days, less than 90 days and nonusers in the depressed population
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180+ Day Antidepressant
Use
<180 day Antidepressant Use

No Antidepressant

Figure 4.12: Survival in the Depressed Population for Those Who Continuously Use
Antidepressants for 180 days: Kaplan-Meier estimates for months survived since breast
cancer diagnosis in antidepressant users for at least 180 days, less than 180 days and nonusers in the depressed population
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1 + Year Antidepressant Use
< 1 Year Antidepressant Use
No Antidepressant

Figure 4.13 Survival in the Depressed Population for Those Who Continuously Use
Antidepressants for 1 Year: Kaplan-Meier estimates for months survived since breast
cancer diagnosis in antidepressant users for at least 1 year, less than 1 year and non-users
in the depressed population
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Table 4.1: Baseline Characteristic of the Depressed and Non-Depressed Populations

History of Depression*
Hormone therapy type
SERM only
AI only
Charlson Score *
0
1
2+
Stage *
0
1
3
Grade
1
2
3+
Tumor Size in mm*
Initial surgery*
breast conserving
mastectomy
Radiation therapy*
Chemotherapy
SEER site *
orth east
North central
South
West
Race*
White
Black
Other

Non-Depressed
(N= 9,398)
8.62

Depressed
(N= 1,073)
43.71

18.7
81.3

18.17
81.8

58.84
7.81
33.35

53.31
9.69
37

6.39
54.83
30.93
7.84

4.57
49.3
34.76
11.37

28.15
51.29
20.56
18.72

26.47
51.35
22.18
20.82

62.16
37.84
49.8
19.4

53.96
46.04
44.36
20.97

22.43
12.1
25.15
40.32

21.9
13.05
29.73
35.32

85.12
6.9
7.98

89.75
4.94
5.31

0.001

<.0001

0.33

0.0002
<.0001

0.0007
0.22
0.002

0.0002

Age
65-74
75-84
85+
Urban
Married *

p-value
<.0001
0.7

0.071
54.01
36.77
9.21
87.71
43.2
76

52.38
36.25
11.37
87.33
37.28

0.72
0.0002

Non-Depressed
(N= 9,398)
Median Income of Zip
Code*
<30K
30-49K
50K+

Depressed
(N= 1,073)

p-value
0.0016

12.92
45.58
41.5

15.75
47.81
36.44

Table 4.1: Those with an * indicate significant differences at p<.05 between groups. Chisquare analysis was used to compare between those who were depressed and not
depressed.
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Table 4.2 Baseline Characteristics of Antidepressant Users and Non-Users in the
Depressed Population

History of Depression*
Hormone therapy type
SERM only
AI only
Charlson Score
0
1
2+
Stage
0
1
2
3
Grade *
1
2
3+
Initial surgery
breast conserving
mastectomy
Radiation therapy
Chemotherapy
SEER site
North east
North central
South
West
Race
White
Black
Other
Age*
65-74
75-84
85+
Urban
Married
Median Income of Zip

No Antidepressant
(N=409)
37.9

Antidepressant
(N=664)
47.29

18.58
81.42

17.92
82.08

49.39
11.25
39.36

55.72
8.73
35.54

5.38
46.7
35.21
12.71

4.07
50.9
34.49
10.54

21.03
55.01
23.96

29.82
49.1
21.08

56.72
43.28
43.03
20.54

52.26
47.74
45.18
21.23

25.18
12.22
28.12
34.47

19.88
13.55
30.72
35.84

91.2
4.4
4.4

88.86
5.27
5.87

51.1
34.47
14.43
88.26
34.23

53.16
37.35
9.49
86.75
39.16

p-value
0.003
0.79

0.103

0.399

0.007

0.154

0.49
0.785
0.23

0.455

0.045
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0.468
0.105
0.688

No Antidepressant
(N=409)
Code
<30K
30-49K
50K+
Antidepressant Type
SSRI
SNRI
TCA
other

15.89
46.21
37.9
N/A

Antidepressant
(N=664)

p-value

15.66
48.8
35.54
N/A
51.1
14.2
8.4
24.4

Table 4.2: Those with an * indicate significant differences at p<.05 between groups. Chisquare analysis was used to compare between antidepressant users and non-users.
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Table 4.3: Mean PDC values for Depressed and Non-Depressed Patients by Quarter
Quarter Depression No Depression
*1
86.81
89.87
*2
80.48
84.78
*3
77.21
81.34
*4
74.56
78.83
*5
73.07
77.56
*6
71.98
76.60
*7
71.30
75.72
*8
70.13
74.96
*9
68.44
74.49
*10
67.73
73.76
*11
66.77
73.18
*12
66.86
72.36
*13
65.96
71.98
*14
63.85
70.74
*15
61.27
69.46

Table 4.3: The * indicates a significant difference (p<.05) between mean PDC values for
the depressed and non-depressed group from the students t-test.
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Table 4.4 Adherence to Hormone Therapy in the Depressed Population

Repeated Measure *
Depression *
History of Depression*
Hormone therapy type
SERM only
AI only*
Charlson Score
0
1
2+
Stage
0
1
2
3
Grade
1
2
3+
Initial surgery
breast conserving
mastectomy *
Radiation therapy
Chemotherapy
SEER site
North east
North central*
South*
West
Race
White
Black
Other *
Age
65-74
75-84*
85+*
Urban
Married

Odds ratio
0.911
0.81
0.85

95% CI
0.91-0.92
0.71, 0.93
0.75, 0.96

0.60

0.53, 0.67

1.01
0.99

0.87, 1.16
0.91, 1.07

1.01
1.10
0.94

0.84, 1.20
0.91, 1.33
0.74, 1.19

1.05
1.04

0.96, 1.15
0.93, 1.17

1.15
1.05
0.91

1.04, 1.28
0.95, 1.15
0.82, 1.01

0.72
0.86
0.99

0.63, 0.83
0.76, 0.97
0.89, 1.10

1.10
1.50

0.92, 1.30
1.28, 1.77

0.87
0.85
0.85
1.06

0.80, 0.94
0.74, 0.99
0.74, 0.98
0.98, 1.15
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Median Income of Zip
Code
<30K
30-49K
50K+

Odds ratio

95% CI

1.01
0.91

0.88, 1.15
0.79, 1.05

Table4.4: Those with an * indicate significant results at p<.05. Blank cells indicate
referent group in analysis.
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Table 4.5 Mean PDC Values for Antidepressant Users and Non-Users in the Depressed
Population
Quarter Antidepressant No antidepressant
1
86.74
86.93
2
80.89
79.81
3
77.76
76.31
4
75.50
72.99
5
73.77
71.85
6
71.93
72.09
7
71.68
70.59
8
71.03
68.41
9
69.55
66.40
10
68.54
66.21
11
67.78
64.89
12
67.97
64.84
13
67.60
62.89
14
64.38
62.93
15
61.35
61.14

Table 4.5: Differences in the mean PDC value for antidepressant users and non-users in
the depressed population were tested with the student's t-test. There were no significant
difference at p<.05.
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Table 4.6 Adherence to Hormone Therapy for Antidepressant Users and Non-Users in the
Depressed Population

Repeated Measure
Antidepressant
Antidepressant Use
< 90 days
90-179 days
180-364 days
365+ days*
History of Depression
Hormone therapy type
SERM only
AI only*
Charlson Score
0
1
2+
Stage
0
1
2
3
Grade
1
2
3+
Initial surgery
breast conserving
mastectomy *
Radiation therapy
Chemotherapy
SEER site
North east
North central
South*
West
Race
White
Black

Odds Ratio
0.90
0.79

95% CI
0.88, 0.92
0.55, 1.13

1.21
1.08
2.42
0.94

0.73, 1.99
0.70, 1.66
1.61, 3.65
0.74, 1.21

0.69

0.48, 0.99

0.97
1.05

0.62, 1.51
0.81, 1.36

0.75
0.82
0.71

0.42, 1.36
0.44, 1.51
0.34, 1.47

0.89
1.08

0.74, 1.30
0.76, 1.55

1.76
1.12
0.78

1.30, 2.39
0.83, 1.50
0.57, 1.08

0.86
0.64
0.89

0.56, 1.31
0.45, 0.93
0.64, 1.24

0.83

0.47, 1.46
84

Other

Odds Ratio
1.42

95% CI
0.83, 2.44

Age
65-74
75-84
85+
Urban
Married
Median Income of Zip
Code
<30K
30-49K
50K+

0.84
0.86
0.80
0.93

0.64, 1.09
0.55, 1.33
0.52, 1.22
0.71, 1.21

1.05
0.86

0.73, 1.50
0.57, 1.29

Table 4.6: An * indicates significant results at p<.05. Blank cells indicate referent group
in analysis.
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Table 4.7 Risk of Non-Persistence in the Depressed Population

Depression
History of Depression*
Hormone therapy type
SERM only
AI only
Charlson Score
0
1
2+*
Stage
0
1*
2*
3*
Grade
1
2
3+*
Initial surgery
breast conserving
mastectomy *
Radiation therapy
Chemotherapy*
SEER site
North east
North central
South
West *
Race
White
Black
Other
Age
65-74
75-84
85+*

Hazard Ratio
1.06
1.28

95% CI
0.98, 1.14
1.19, 1.37

0.98

0.93, 1.04

1.07
1.13

0.98, 1.16
1.08, 1.18

1.14
1.17
1.40

1.04, 1.25
1.06, 1.29
1.24, 1.59

1.04
1.08

0.98, 1.09
1.01, 1.15

0.93
0.97
1.17

0.88, 0.98
0.91,1.02
1.10, 1.25

1.08
1.07
1.10

0.99, 1.18
1.00, 1.15
1.04, 1.17

1.01
0.96

0.92, 1.10
0.88, 1.04

1.00
1.24

0.96, 1.05
1.14, 1.34

0.97
0.97

0.90, 1.04
0.92, 1.01

Urban
Married
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Hazard Ratio

95% CI

0.99
1.03

0.92, 1.07
0.95, 1.11

Median Income of Zip Code
<30K
30-49K
50K+

Table 4.7: An * indicates significant results at p<.05. Blank cells indicate referent group
in analysis.
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Table 4.8 Risk of Non-Persistence for Antidepressant Users in the Depressed Population

Antidepressant
Antidepressant Use
< 90 days
90-179 days
180-364 days*
365+ days*
History of Depression
Hormone therapy type
SERM only
AI only
Charlson Score
0
1
2+
Stage
0
1
2
3*
Grade
1
2
3+
Initial surgery
breast conserving
mastectomy
Radiation therapy
Chemotherapy*
SEER site
North east
North central
South
West
Race
White
Black
Other

Hazard Ratio
1.04

95% CI
0.85, 1.27

1.12
1.32
0.55
1.09

0.87, 1.45
1.02, 1.69
0.44, 0.70
0.95, 1.26

0.86

0.71, 1.02

1.23
1.06

0.97, 1.56
0.91, 1.22

1.32
1.29
1.83

0.94, 1.84
0.91, 1.82
1.23, 2.74

1.01
1.04

0.86, 1.20
0.85, 1.28

0.86
0.91
1.42

0.72, 1.02
0.77, 1.08
1.18, 1.72

1.05
1.19
1.20

0.81, 1.35
0.97, 1.47
0.99, 1.46

1.26
1.24

0.90,1.76
0.92, 1.68
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Hazard Ratio

95% CI

0.92
1.46
0.98
.98

0.78, 1.06
1.16, 1.83
0.77, 1.25
0.85, 1.14

0.99
1.00

0.79, 1.24
0.78, 1.28

Age
65-74
75-84
85+*
Urban
Married
Median Income of Zip
Code
<30K
30-49K
50K+

Table 4.8: An * indicates significant results at p<.05. Blank cells indicate referent group
in analysis.
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Table 4.9 Adjusted Estimate for Survival in the Depressed Population

Depression *
History of Depression
Hormone therapy type
SERM only
AI only
Charlson Score
0
1*
2+*
Stage
0
1*
2*
3*
Grade
1
2*
3+*
Initial surgery
breast conserving
mastectomy *
Radiation therapy*
Chemotherapy
SEER site
North east
North central
South
West
Race
White
Black *
Other *

Estimate
-0.36
-0.07

95% CI
-0.48, -0.25
-0.18, 0.04

0.07

-0.03, 0.17

-0.29
-0.40

-0.42, -0.16
-0.48, -0.32

-0.47
-0.69
-1.23

-0.68, -0.25
-0.91, -0.47
-1.47, -0.98

-0.14
-0.27

-0.23, -0.05
-0.39, -0.16

0.17
0.42
-0.01

0.07, 0.26
0.33, 0.51
-0.12, 0.09

0.001
-0.07
0.05

-0.14, 0.14
-0.18, 0.05
-0.05, 0.15

-0.19
0.18

-0.33, -0.05
0.02, 0.34

-0.51
-1.02

-0.60, -0.42
-1.14, -0.90

Age
65-74
75-84*
85+*
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Urban
Married *
Median Income of Zip Code
<30K
30-49K
50K+

Estimate
0.12
0.25

95% CI
-.01, 0.24
0.17, 0.34

0.03
0.08

-0.09, 0.15
-0.06, 0.21

Table 4.9: An * indicates significant results at p<.05. Blank cells indicate referent group
in analysis. The natural exponent of estimates represents percent reduction or increase in
survival.
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Table 4.10 Unadjusted Costs for Depressed and Non-Depressed Patients
Year From Breast Cancer
Diagnosis
1 (N=9,398 , N=1,073)
2 (N= 8,985 , N=970)
3 (N=6,713 , N=664)
4 (N= 4,151 , N=395)
5 (N= 1,979 , N=166)

Non-Depressed
$
830,524.43
$
33,057.19
$
22,918.75
$
18,296.51
$
6,388.32

Depressed
$ 771,597.74
$
60,376.09
$
38,931.67
$
24,830.93
$
12,285.88

p-value
0.34
<.0001
<.0001
0.12
0.03

Table 4.10: Median per patient per year cost that Medicare paid from date of breast
cancer diagnosis is reported. Year represents number of years since breast cancer
diagnosis. The first N value indicates the number of non-depressed patients and the
second N value indicates the number of depressed patients in that year. P-value is
reported from Wilcoxon ranked sum test for non-parametric distributions.
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Table 4.11 General Linear Model Estimates for Per Patient per Year Cost for Those Who
are Depressed

Intercept
Repeated Measure
Depression
History of Depression
Hormone therapy type
SERM only
AI only
Charlson Score
0
1*
2+*
Stage
0
1
2*
3*
Grade
1
2
3+
Initial surgery
breast conserving
mastectomy *
Radiation therapy*
Chemotherapy*
SEER site
North east
North central*
South*
West
Race
White
Black *
Other
Age
65-74
75-84
85+*

Parameter Estimate
12.25
-1.46

95% CI
11.74, 12.75
-1.41, -1.50

0.10
-0.14

-0.06, 0.26
-0.285, 0.004

0.09

-0.09, 0.27

0.25
0.43

0.03, 0.46
0.28, 0.58

0.15
0.41
0.42

-0.09, 0.39
0.14, 0.68
0.11, 0.73

-0.11
-0.02

-0.30, 0.07
-0.24, 0.20

0.16
0.23
0.19

0.01, 0.31
0.09, 0.37
0.03, 0.36

-0.47
-0.30
-0.05

-0.68, -0.25
-0.48, -0.11
-0.21, 0.12

0.52
0.20

0.18, 0.86
-0.15, 0.55

-0.02
-0.44

-0.17, 0.14
-0.62, -0.26
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Urban
Married
Median Income of Zip Code
<30K
30-49K*
50K+*
Total months in parts A and B
Total months in part D*

Parameter Estimate
0.11
0.01

95% CI
-0.16, 0.38
-0.12, 0.14

-0.42
-0.45
0.01
0.08

-0.76, -0.08
-0.83, -0.08
-0.01, 0.04
0.05, 0.12

Table 4.11: An * indicates significant results at p<.05. Blank cells indicate referent
group in the analysis. The natural exponent of the estimate added to the intercept
represents the total per patient per year cost to Medicare for that group.
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Table 4.12 Unadjusted Costs for Antidepressant Users and Non-Users in the Depressed
Population

Year From Breast Cancer
Diagnosis
1 (N=409, N=664)
2 (N=367, N=603)
3 (N=240, N=424)
4 (N=132, N=263)
5 (N=56, N=110)

No antidepressant
$
771,597.74
$
43,211.73
$
30,458.02
$
21,750.93
$
6,176.56

Antidepressant
$
771,996.68
$
68,598.79
$
41,576.25
$
27,190.20
$
16,207.32

p-value
0.65
0.02
0.06
0.23
0.47

Table 4.12: Median per patient per year cost that Medicare paid in the depressed
population from date of breast cancer diagnosis is reported. Year represents number of
years since breast cancer diagnosis. The first N value indicates the number of patients in
the no antidepressant group and the second N value indicates the number of patients in
the antidepressant group for that year. P-value is reported from Wilcoxon ranked sum
test for non-parametric distributions.
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Table 4.13 General Linear Model Estimate for Cost in Antidepressant Users in the
Depressed Population

Intercept *
Repeated measure *
Antidepressant
Antidepressant Use
< 90 days
90-179 days
180-364 days
365+ days
History of Depression
Hormone therapy type
SERM only
AI only
Charlson Score
0
1
2+*
Stage
0
1
2
3
Grade
1
2*
3+*
Initial surgery
breast conserving
mastectomy
Radiation therapy
Chemotherapy
SEER site
North east
North central *
South*
West
Race
White
Black *

Parameter Estimate
11.92
-2.07
0.17
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95% CI
10.82, 13.01
-1.88
-0.19, 0.52

-0.03
-0.08
-0.05
-0.20

-0.40, 0.34
-0.43, 0.26
-0.41, 0.31
-0.46, 0.06

0.12

-0.16, 0.40

0.42
0.29

-0.14, 0.99
0.04, 0.53

0.13
0.39
0.10

-0.47, 0.74
-0.26, 1.04
-0.58, 0.78

0.52
0.59

0.25, 0.79
0.28, 0.91

0.15
0.21
-0.06

-0.15, 0.45
-0.04, 0.46
-0.36, 0.24

-0.53
-0.54
0.13

-0.91, -0.16
-0.91, -0.17
-0.27, 0.53

0.98

0.43, 1.52

Other

Parameter Estimate
0.27

95% CI
-0.38, 0.93

Age
65-74
75-84*
85+*
Urban
Married
Median Income of Zip Code
<30K
30-49K*
50K+*
Total months in parts A and B*
Total months in part D*

-0.32
-0.87
0.35
-0.05

-0.61, -0.03
-1.26, -0.49
-0.003, 0.706
-0.34, 0.24

-0.59
-0.61
0.06
0.003

-0.93, -0.26
-0.97, -0.25
0.01, 0.10
0.02, 0.13

Table 4.13: An * indicates significant results at p<.05. Blank cells indicate referent
group in the analysis. The natural exponent of the estimate added to the intercept
represents the total per patient per year cost to Medicare for that group.
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CHAPTER 5 DISCUSSION
5.1 Introduction

The final chapter will provide a discussion of the results and insight for future research
and broader applications. A summary of the results for adherence to hormone therapy, survival
and cost will begin each section. For each outcome, a discussion of the effect of depression on
that outcome will start followed by a discussion of the effect of antidepressant use in the
depressed population on that outcome. After the discussion, limitations will be discussed and
how they affect the results. The chapter will conclude with an overall summary and final
conclusion.

5.2 Adherence to Hormone Therapy

5.2.1 The Association of Depression with Adherence to hormone therapy
Depression was significantly associated with decreased adherence to hormone therapy. A
history of depression was also significantly associated with decreased adherence. In the
literature, mainly prospective studies have been done to determine the association of depression
with adherence to hormone therapy20, 88, 92. In these studies, the association of depressive
symptoms was determined, not the association of clinical depression. Two of these studies20, 88
find a significant decrease in adherence, which the current results corroborate. The third showed
that non-adherers to hormone therapy had a higher prevalence of depressed mood but this was not
significant in the multivariate model used to predict adherence92. A retrospective hospital study
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by Ziller found that depression had non-significant differential effects on adherence depending on
the type of hormone therapy51. Tamoxifen users had a non-significant increase in adherence
while aromatase inhibitor users had a non-significant decrease in adherence. The current results
reflect the finding by Ziller as aromatase inhibitors did have a significant reduction in adherence
compared to the tamoxifen group. This study builds on the existing literature by confirming
existing results in a previously unused data source with a different method of measuring
adherence. While previous work used self-report, pill count, electronic monitoring pill caps or
the medication possession ratio (MPR) 20, 51, 88, 92, percent days covered (PDC) was used in this
study. While the MPR is generally used for estimating adherence in claims data, it can
overestimate adherence114. Percent days covered is a simpler formula that removes the worry of
counting a day twice as can happen with early fills using the MPR114. PDC has been used
previously in measuring hormone therapy adherence in breast cancer22, 36; however, this is the
first time it has been used in determining the association of depression with adherence to
hormone therapy. Using this method, depression is associated with a decrease in adherence to
hormone therapy. This is the first study to use repeated measures to determine the association of
depression with adherence to hormone therapy in a large database. As adherence to hormone
therapy drops over time, the use of repeated measures accounts for this decrease. This is seen
with the significant negative value of the repeated measure variable in the model. The repeated
measure variable corroborates the established studies that show adherence to hormone therapy
drops over time22, 33. One limitation to note is that a causal relationship cannot be established in
this study. As depression was not identified before the start of hormone therapy, the temporal
criteria is not met for Hill’s criteria for causation. There is a potential causal association between
a history of depression and reduced adherence to hormone therapy. As it is definite that a history
of depression is before the start hormone therapy, Hill’s temporal sequence criteria for causality
is met; however, Hill’s other requirements to establish a causal relationship (specificity, strength
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of association etc.) are not present in this study115. Physicians should screen newly diagnosed
breast cancer patients for depression and determine their depression history. This screen would
point to those at greater risk for not adhering to hormone therapy and needing more active follow
up once hormone therapy is initiated.
5.2.2 The Association of Antidepressants in the depressed population with Adherence to hormone
therapy
Continual antidepressant use was associated with significantly improved adherence to
hormone therapy in the depressed sample. Since depression decreases adherence, treating
depression is thought to improve adherence to hormone therapy. In the regression model, those
with continual use of antidepressants had significantly improved adherence. Only two studies
observed any association of antidepressant use and adherence24, 81. Navari found antidepressant
use improved adherence to hormone therapy81, and Trabulsi found that antidepressant use reduced
adherence to hormone therapy24. Trabulsi did not control for depression, so antidepressant use
likely became a proxy for depression and it is unknown how antidepressant use affects adherence
to hormone therapy in the depressed population. Navari looked at those with depressed
symptoms and found that antidepressant use improved adherence to hormone therapy. The
association of antidepressant use in the depressed population is unknown from this study because
Navari only looked at those with depressive symptoms. This is the first study to show any
association of antidepressant use in the depressed population. There is a slight negative
association with general antidepressant use and adherence to hormone therapy. The analysis did
adjust for length of antidepressant use and this negative association could correlate to more severe
depression because claims data does not capture information on depression severity. Future work
in this area would be to adjust for depression severity in determining the association of depression
with adherence to hormone therapy. This study established that any benefit of antidepressant use
on adherence to hormone therapy is with prolonged use of antidepressants. Physicians who
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prescribe antidepressants to breast cancer patients with depression should make it clear to the
patient that they need to be diligent in taking their antidepressant if they want to get any benefit
from taking the antidepressant regarding improving their adherence to hormone therapy.
Diligence in taking one drug is associated with diligence in taking another drug as a patient who
is taking one can easily take a second at the same time. It is possible that just the act of taking an
antidepressant and not the antidepressant itself improves adherence to hormone therapy in
patients with depression. Those who seek treatment for depression likely want to get better and
be more diligent in taking hormone therapy regardless if the antidepressant actively reverses any
chemical imbalance caused by depression47, 116, 117. Future work will be to determine if these
results are consistent in other data sources and if an active ingredient in antidepressants is needed
to achieve the results found in this study.
This is the first study to report an association between antidepressant use and adherence
to hormone therapy in breast cancer patients with depression and provides a new field for
research in breast cancer.

5.3 Persistence to Hormone Therapy

5.3.1 The Association of Depression with persistence to hormone therapy
Those with depression had an increased risk of non-persistence after adjusting for clinical
and demographic characteristics. Those with a history of depression also had a significant
association with non-persistence. This result reflects three of the six published studies19, 29, 52.
This study builds on two of the published studies by using a more stable and direct measure of
depression compared to the previous studies29, 52. Kemp used a questionnaire to determine
depressed mood, which is influenced by when the person fills out the questionnaire and is not a
measure of clinical depression. Aiello Bowles used antidepressant use to determine depression,
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which is not an accurate way of determining depression. Antidepressants are generally used to
treat depression, but they can be used for several purposes in addition to treating depression and
the depressed sample is potentially overestimatmed71. Huiart and Cluze look at the association of
tamoxifen discontinuation and depressive symptoms in the French population19, 90. This study
builds on these studies as it is in the United States and uses a diagnosis of depression instead of
depressed mood or antidepressant use for characterizing those with depression. The study by
Huiart used the same data as Cluze but found a non-significant decrease in non-persistence90. An
important distinction between these two studies is that Cluze looked at early vs late
discontinuation of tamoxifen while Huiart looked at discontinuation in general. Cluze only found
increased non-persistence in those who had late discontinuation of tamoxifen19. These results
could indicate that those with depression are actually going to the doctor early on and are more
motivated to continue therapy. This explanation is also a potential reason for the results seen in
the studies by Hadji and Kostev33, 91. As the studies that show depression improves persistence
are all in Europe, there could be a policy in place for those with depression getting better care,
which would improve persistence. The one study in the United States showed decreased
persistence for those with depression, which this study supports. Further study of differing
policies between the United States and Europe for those with depression might yield the reason
why the European studies indicate a positive association of depression with persistence and the
United States studies indicate a negative association. By definition, those who are not persistent
are not adherent, as those who do not take their medicine for an extended period will not meet the
80% requirement to be adherent. Hypothesis H1A is supported by results from adherence to
hormone therapy and persistence to hormone therapy.
5.3.2 The Association of Antidepressants in the depressed population with persistence to hormone
therapy
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Those who used antidepressants continually had significantly improved persistence in the
depressed population. Of interest, continual use of antidepressants was significantly associated
with increased persistence after adjusting for clinical and demographic characteristics. General
antidepressant use was associated with a non-significant increase in the risk of non-persistence
when adjusting for clinical and demographic characteristics; however, as this was adjusted for
time, it is likely that this increase in risk reflects more severe depression. This result supports the
only previously reported study of antidepressant use and adherence by Cluze19, which showed
decreased persistence for those taking antidepressants. Building on Cluze's study, this study also
accounts for length of time using antidepressants. Those using antidepressants longer show
improved persistence compared to those who do not. A potential explanation is those who
continue taking antidepressants have a more positive outlook on life, which could lead to them to
be more persistent23.
Results for the association of antidepressant use with adherence to hormone therapy and
persistence to hormone therapy indicate that duration is a critical component in improving these
outcomes in breast cancer patients with depression. As hypothesis H1B does not take into
account the duration of antidepressant use, the results do not support H1B.

5.4 Survival

5.4.1 The Association of Depression with Survival
Depression was associated with a significant decrease in survival and a history of
depression was also associated with a decrease in survival. This is consistent with published
literature54, 55, 57, 89. The study by Hjerl examined the association of survival with post-operative
depression , controlling for pre-operative depression89. As Hjerl's definition of pre and postoperative is based on diagnosis, this study looked at a similar definition of depression and found
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similar results. Of the three United States based studies, two studies looked at concurrent
depression55, 57 and one looked at a history of depression54. Studies that observed concurrent
depression did not adjust for a history of depression, which has a significant impact on survival54,
89

. This is the first study to determine the association survival with depression adjusting for a

history of depression. The values reported in this study reflect published work both with
concurrent and a history of depression and are the first to report both in the United States. These
results support hypothesis H2A that there is a negative association of depression with survival.
5.4.2 The Association of Antidepressants in the depressed population with Survival
Continual use of antidepressants significantly improved survival in the depressed sample
with longer time taking antidepressants indicating improved survival. The Kaplan-Meier curves
indicate that those who are on antidepressants but are not using them have worse survival
compared to those who do not use them at all. This would indicate to physicians that if they
prescribe breast cancer patients an antidepressant they should emphasize the importance of using
the antidepressant. Interestingly, at 90 days those taking antidepressants continually are similar
to those with no drug while at 365 days those not continually taking an antidepressant are similar
to those without an antidepressant. As the 180-364 day curve is in between the 90-179 and the
365+ day curves, antidepressant use for over 90 days is necessary to improve survival in the
depressed population. For physicians, if they prescribe antidepressants for the depressed
population, they should prescribe for at least 180 days in order to improve survival in their
patient. This time period potentially explains why there was no difference between fluoxetine
users and placebo patients in the study by Fisch. In Fisch's study, fluoxetine was only given for
52 days, which falls into the 90 day window showing no difference between users and non-users
in this study70.
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These results add to the existing literature of the impact of treating depression on survival. While
the literature indicates that decreasing depression symptoms improves survival82, it has not been
shown that treating depression with group therapy or fluoxetine improves survival64, 70. It should
be noted that the published results for fluoxetine and group therapy were not in the depressed
population. One study found a negative association of SSRI (class of antidepressants) use on
survival; however, this was not in the depressed population78. Another study that looked at some
antidepressants and other drugs that inhibit CYP2D6 found a non-significant improvement on
survival28. Again, this was not in the depressed population so the impact of antidepressants on
survival in the depressed population was unknown until this study. The marked difference
between those with continual antidepressant use and those with non-continuous use could explain
why worse survival is indicated in published studies; these patients were not continual users of
antidepressants.
As duration of antidepressant use is an important factor for improved survival, hypothesis
H2B is not supported.

5.5 Cost

5.5.1 The Association of Depression with Cost
Those with depression had higher median direct medical cost compared to those without
depression. No significant increase in cost was shown for those with depression in the model
adjusting for clinical and demographic characteristics. The incremental cost of depression was
$21,978.75, not significant, per patient per year. The non-significant increase in cost is possible
because this study is from Medicare's perspective and is in the elderly population, who likely has
multiple co-morbidities. These patients would already be going to the physician's office, so one
visit would take care of multiple co-morbidities, which would not significantly impact cost. Also,
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more advanced stage was associated with increased cost, indicating severity of cancer. As these
factors are all correlated, the non -significant increase in cost for depression is explained as the
significant increase is from more severe cancers and more co-morbidities are the cost drivers
instead of depression. Another reason for the non-significant increase is those with depression
might stop taking medications or stop visiting their physician. This would reduce cost because
they are not utilizing these services; however, these patients are probably at a higher risk of being
hospitalized and have increased cost at the hospital. The magnitude of increased cost for these
patients depends on the difference between the increased hospital cost and reduced physician visit
and pharmacy cost. Also, this study only calculated drug, physician visit, outpatient and inpatient
hospital cost. Costs for home health services were not included. Those with depression might be
more likely to use home health services but would not be captured in this study and could explain
the non-significant increase in cost.
The only published cost for depression and breast cancer indicated that those with
depression had an average yearly cost of $15,471 compared to $8,297 for the non-depressed
group60, 93. The study was in breast cancer survivors from the military database and is did not
report this as incremental cost. The published cost is to the Department of Defense (DOD) and
not Medicare. There are key differences in these populations which would explain the
differences in cost between this study and Jeffery’s. Jeffery looked at veterans and a younger
population compared to this study, which looked at the older population in Medicare. Those who
are younger are likely to be more healthy and have lower medical cost compared to those who are
older and in Medicare. This difference could explain the higher cost found in this study
compared to Jeffery’s. Also, Medicare and the DOD likely have different policies on what they
will and will not cover for patients. This difference in coverage could also explain why there is a
difference in these two studies as the DOD may not cover all the services Medicare does or has a
different reimbursement policy that would explain differences in this study and Jeffery’s.
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Hypothesis H3A is not supported as depression did not significantly increase cost; however, the
results do indicate an increase in cost for patients with depression. It is possible that in a younger
population with fewer co-morbidities, depression significantly increases cost.
5.5.2 The Association of Antidepressants in the depressed population with Cost
Antidepressant use did not significantly increase cost in the depressed population. The
incremental cost to Medicare for antidepressant use is $27,840.50 per patient per year. This nonsignificant increase in cost is consistent with literature for cost of psychosocial interventions in
the breast cancer population83, 99, 100. Continual antidepressant use for 90+ days was associated
with a non-significant reduction in cost. This indicates that these patients are probably reducing
their cost because they are likely not having as many hospital visits but not enough to offset the
cost of the antidepressant. As mentioned before, these patients already incur significant medical
cost elsewhere and the additional drug cost is not a significant increase from Medicare’s
perspective. These results indicate that continual use of antidepressants potentially reduces the
cost to Medicare.

5.6 Strengths

This study has two major strengths: external and statistical validity. This study has
external validity (results generalizable to a broader population) due to the use of SEER-Medicare.
SEER-Medicare is representative of the entire Medicare population and so these results are
generalizable to the full Medicare breast cancer population with hormone receptor positive
cancer. The analysis used has statistical validity; a relationship is established between depression
or antidepressant use and some of the studied outcomes. The analysis uses a repeated measures
design to follow patients over time, so it accounts for changes in the outcome over time. As
adherence and cost change over time, repeated measures allows for a more accurate
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representation of what happens in the general population, which also improves external validity.
Repeated measures also increase the statistical power to detect differences and allows for multiple
observations per person, which improves statistical validity as a smaller population can be used to
detect statistically significant differences. Repeated measures plus the large sample size provides
statistical power to detect significant differences between groups. Model assumptions were
checked and appropriate analysis was done if assumptions were violated, which strengthens the
statistical validity of this study as the proper analysis was done for the data.
This study is not able to establish causality, but there are strengths with the association of
depression and survival that should be noted. The association of depression with survival fulfills
some of Hill’s criteria for causality but not all. Hill’s criteria for strength, temporal order,
biological plausibility and consistency are present as there is a marked increase in the risk of
death for those with depression, there is a biological link of depression with survival, the
literature consistently reports a negative association of depression with survival and depression is
diagnosed before death. Hill’s criteria for specificity is partially fulfilled because the analysis
adjusts for various confounders that would impact survival, including a history of depression but
cannot adjust for all factors that impact survival. Other strengths of this study is the adjustment
for a prior diagnosis of depression and observing antidepressant use, general and continual, in the
depressed sample. No United States study has reported the association of depression with
adherence to hormone therapy, survival and cost adjusting for a prior diagnosis of depression.
The literature reports a prior diagnosis of depression has a significant association with these
outcomes. Adjusting for a prior diagnosis and several confounders allows for a more precise
estimate for the association of depression with these outcomes. The association of antidepressant
use in the depressed population has not been reported and is a strength of this study. Studies that
report the association of antidepressant use with these outcomes in the non-depressed population
could reflect a depression diagnosis instead of the treatment. The addition of a length of
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antidepressant use adds strength to this study because it distinguishes those who are short term
users from those with extend use. This addition captures the benefit of antidepressant use and the
general antidepressant variable would likely capture the severity of depression. Hence, the
negative association found in this study.

5.7 Limitations

The first limitation in this study is that depression is under reported in Medicare claims54.
This is more evident in cancer patients, who are less likely to be diagnosed with depression due to
the side effects of chemotherapy and radiation being similar to depression37. This limitation
indicates that those who are in the non-depressed group are likely similar to those in depressed
group. The more homogenous the groups, the less likely it is to find a difference between them.
This limitation would likely reduce the power to detect differences between antidepressant users
and non-users. However, the use of repeated measures and as both groups had a sample size over
300, this study was likely sufficiently powered to detect differences between users and non-users.
The second limitation is using claims to measure adherence. While previous work has
been done using part D to measure use of hormone therapy, there are limitations to consider11.
One important limitation is there is no guarantee that a person actually takes the medicine after
they fill it at the pharmacy. Those with multiple fills are likely to be taking hormone therapy as it
is unlikely a person would continue to spend money on something they are not using. Also, there
is no way to determine why a person was not adherent or non-persistent. Was it due to side
effects or some other reason? One reason could be a person was able to get free samples from
their physician or a clinical trial11. Those who receive free samples would not have claims in part
D and could be counted as non-adherent when they actually were. This would make it more
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difficult to detect an association with adherence to hormone therapy, as the two groups would be
more similar instead of different.
A limitation in looking at antidepressant use in the depressed population is the inability to
control for other types of depression treatment. This limitation would potentially reduce
differences between the two groups, and make it more difficult to detect an association of
antidepressants with the studied outcomes in the depressed population. As it has been shown that
group therapy is effective in reducing depressive symptoms65, those in the non-antidepressant
group could still benefit from reduced depressive symptoms by participating in group therapy.
Those with depression generally had a history of depression and are likely already being treated
with group therapy or antidepressants. As severity of depression is unable to be measured, the
antidepressant variable and history variable could be capturing the association of depression
severity in addition to what they intend to capture. As this study used a duration of antidepressant
use variable in addition to a general use variable, the benefit of antidepressant use is likely
captured in the use instead of the general variable and this study works with this limitation.

5.8 Policy Implications

These results indicate that time is an important factor with breast cancer patients.
Adherence to hormone therapy reduces over time, survival reduces over time and cost reduces
over time. Physicians treating breast cancer patients need to be more aware of the issue of
adherence to hormone therapy reducing over time. As it is the long term use of hormone therapy
that improves survival, effort should be made to focus on improving adherence to hormone
therapy after the first year. Incentives could be put in place for physicians to see their patients
more often or for patients to prove they are taking hormone therapy as prescribed. These
incentives would hopefully lead to better adherence and improved survival in these patients. The
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feasibility of such an incentive program should be tested and determined if the additional cost of
the incentive is worth the gain in survival.
These results indicate that depression negatively affects adherence to hormone therapy,
survival and cost. For breast cancer patients, depression screening should be considered as a
routine protocol to identify those with depression and start them on antidepressants in order to
improve their chances of survival. Physicians should be made aware that depression is an issue
for breast cancer patients and these patients need increased guidance to stay with their hormone
therapy treatment to improve survival. For physicians who want to prescribe antidepressants to
treat patients with depression, they should be made aware that patients need to be on an
antidepressant for at least 180 days to start benefiting from this drug. This study shows that cost
is not significantly increased with continual use of antidepressants and over time cost may be
reduced. Potential incentives could be put in place for physicians who treat depression in breast
cancer with antidepressants for making sure patients stick with their regimen for at least 180 days.
Going forward a cost effectiveness analysis should be done to determine the feasibility of
screening breast cancer patients for depression and then using antidepressants as a treatment.

5.9 Conclusion

This study shows for the first time the association of depression with hormone therapy
adherence, survival and cost in breast cancer patients while controlling for a history of
depression. Consistent with the literature, this study shows that depression has a negative impact
on adherence to hormone therapy, survival and cost. For the first time, the association of
antidepressants with hormone therapy adherence, survival and cost in the depressed breast cancer
population was examined. These results indicate that long term antidepressant use improves
adherence and survival and potentially reduce cost.
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Further study is needed to determine how robust these results are and if they are
generalizable to entire breast cancer population and not just the Medicare breast cancer
population.
In conclusion, extended antidepressant use in the depressed breast cancer population
provides positive benefits to these patients by improving adherence to hormone therapy and
survival.
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APPENDIX A: ADDITIONAL INFORMATION

Table A.1 Sample Size for the Association of Depression with Adherence to Hormone Therapy
Quarter
Depressed
Non-Depressed
1,073
9,398
1
1,036
9,211
2
973
8,898
3
882
8,177
4
793
7,541
5
716
6,915
6
638
6,249
7
550
5,460
8
496
4,910
9
429
4,336
10
362
3,776
11
280
3,073
12
241
2,577
13
195
2,089
14
148
1,611
15
Table A.1: The number of patients identified in each quarter who have a measure of adherence to
hormone therapy for those with and without depression
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Table A.2 Sample Size for the Association of Antidepressant Use with Adherence to Hormone
Therapy for those with Depression
Quarter
Antidepressant Use
No Antidepressant Use
664
409
1
643
393
2
605
368
3
549
333
4
503
290
5
458
258
6
416
222
7
361
189
8
322
174
9
280
149
10
235
127
11
180
100
12
157
84
13
124
71
14
91
57
15
Table A.2 Number of patients identified with depression who either took or did not take
antidepressant for each quarter with a measure of adherence to hormone therapy

Table A.3 Sample Size for Per Patient Per Year Cost for Depressed and Non-Depressed Patients

Year
Depressed
Non-Depressed
1,073
9,398
1
970
8,985
2
664
6,713
3
395
4,151
4
166
1,979
5
Table A.3: The number of patients identified in each year who have a measure of cost for those
with and without depression
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Table A.4 Sample Size for Per Patient Per Year Cost for Antidepressant Users and Non-Users in
Patients with Depression

Year
Antidepressant Use
No Use of Antidepressant
664
409
1
603
367
2
424
240
3
263
132
4
110
56
5
Table A.4: The number of patients with depression identified in each year with antidepressant use
or no use who have a measure of cost
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Table A.5 Association of 90 Day Use of Antidepressants with Survival

Estimate
Antidepressant Category
did not use for at least 90 days
no antidepressant
used for at least 90 days
Hormone therapy type
SERM only
AI only
Charlson Score
0
1*
2+*
Stage
0
1*
2*
3*
Grade
1
2
3+
Initial surgery
breast conserving
mastectomy *
radiation therapy*
chemotherapy
SEER site
north east
north central
south
west
Race
white
black
other
Age
65-74
75-84*
85+*
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95% CI

0.99
0.93

-0.31
-0.37

2.29
2.22

0.01

-0.27

0.29

-0.63
-0.37

-0.95
-0.59

-0.30
-0.15

-0.78
-1.05
-1.36

-1.47
-1.75
-2.09

-0.08
-0.35
-0.60

-0.22
-0.21

-0.48
-0.52

0.04
0.10

0.30
0.36
0.07

0.05
0.11
-0.20

0.54
0.60
0.34

0.09
-0.01
0.20

-0.27
-0.32
-0.09

0.46
0.31
0.47

-0.33
-0.17

-0.75
-0.63

0.08
0.28

-0.36
-0.89

-0.59
-1.21

-0.13
-0.57

Estimate
-.01
0.29

Urban
Married *
Median Income of Zip Code
<30K
30-49K
50K+

0.11
0.23

Table A.5: An * indicates significant results at p<.05
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95% CI
-0.36
0.34
0.06
0.53

-0.20
-0.12

0.42
0.59

Table A.6 Association of 180 Day Use of Antidepressants with Survival
Estimate
Antidepressant Category
no antidepressant
did not use for at least 180 days
used for at least 180 days
Hormone therapy type
SERM only
AI only*
Charlson Score
0
1*
2+*
Stage
0
1*
2*
3*
Grade
1
2
3+
Initial surgery
breast conserving
mastectomy *
radiation therapy*
chemotherapy*
SEER site
north east
north central
south
west
Race
white
black *
other
Age
65-74
75-84*
85+*
Urban

95% CI

-0.21
0.12

-0.44
-0.14

0.03
0.38

0.03

-0.25

0.31

-0.61
-0.37

-0.94
-0.59

-0.29
-0.15

-0.79
-1.04
-1.34

-1.48
-1.74
-2.09

-0.09
-0.34
-0.60

-0.21
-0.18

-0.46
-0.49

0.05
0.13

0.28
0.35
0.07

0.04
0.10
-0.20

0.52
0.60
0.34

0.13
0.04
0.19

-0.24
-0.27
-0.10

0.49
0.35
0.47

-0.34
-0.18

-0.75
-0.63

0.07
0.28

-0.35
-0.88
-.01

-0.58
-1.20
-0.36

-0.12
-0.57
0.34
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Married *
Median Income of Zip Code
<30K
30-49K
50K+

Estimate
0.29

0.13
0.26

Table A.6: An * indicates significant results at p<.05
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95% CI
0.06
0.52

-0.17
-0.09

0.44
0.61

Table A.7 Association of 1 Year Use of Antidepressants with Survival
Estimate
Antidepressant Category
used for at least 365 days
did not use for at least 365 days*
no antidepressant*
Hormone therapy type
SERM only
AI only*
Charlson Score
0
1*
2+*
Stage
0
1*
2*
3*
Grade
1
2
3+
Initial surgery
breast conserving
mastectomy *
radiation therapy*
chemotherapy*
SEER site
north east
north central
south
west
Race
white
black
other
Age
65-74
75-84*
85+*
Urban

95% CI

-0.92
-0.79

-1.51
-1.39

-0.33
-0.19

0.03

-0.24

0.31

-0.60
-0.34

-0.92
-0.56

-0.28
-0.12

-0.81
-1.06
-1.37

-1.50
-1.76
-2.11

-0.12
-0.36
-0.63

-0.21
-0.19

-0.47
-0.50

0.04
0.12

0.30
0.37
0.07

0.05
0.12
-0.20

0.54
0.61
0.34

0.12
0.02
0.20

-0.26
-0.28
-0.08

0.47
0.33
0.48

-0.32
-0.15

-0.73
-0.60

0.09
0.31

-0.35
-0.87
-.02

-0.58
-1.19
-.38

-0.13
-0.56
0.33
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Married *
Median Income of Zip Code
<30K
30-49K*
50K+

Estimate
0.27

0.12
0.24

Table A.7 An * indicates significant results at p<.05
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95% CI
0.04
0.5

-0.18
-0.11

0.43
0.59

